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Claire Li 
Modeling and simulation applications with potential impact in drug development and 
patient care 
         Model-based drug development has become an essential element to potentially 
make drug development more productive by assessing the data using mathematical and 
statistical approaches to construct and utilize models to increase the understanding of the 
drug and disease. The modeling and simulation approach not only quantifies the 
exposure-response relationship, and the level of variability, but also identifies the 
potential contributors to the variability. I hypothesized that the modeling and simulation 
approach can: 1) leverage our understanding of pharmacokinetic-pharmacodynamic (PK-
PD) relationship from pre-clinical system to human; 2) quantitatively capture the drug 
impact on patients; 3) evaluate clinical trial designs; and 4) identify potential contributors 
to drug toxicity and efficacy. The major findings for these studies included: 1) a 
translational PK modeling approach that predicted clozapine and norclozapine central 
nervous system exposures in humans relating these exposures to receptor binding kinetics 
at multiple receptors; 2) a population pharmacokinetic analysis of a study of sertraline in 
depressed elderly patients with Alzheimer’s disease that identified site specific 
differences in drug exposure contributing to the overall variability in sertraline exposure; 
3) the utility of a longitudinal tumor dynamic model developed by the Food and Drug 
Administration for predicting survival in non-small cell lung cancer patients, including an 
exploration of the limitations of this approach; 4) a Monte Carlo clinical trial simulation 
approach that was used to evaluate a pre-defined oncology trial with a sparse drug 
concentration sampling schedule with the aim to quantify how well individual drug 
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exposures, random variability, and the food effects of abiraterone and nilotinib were 
determined under these conditions; 5) a time to event analysis that facilitated the 
identification of candidate genes including polymorphisms associated with vincristine-
induced neuropathy from several association analyses in childhood acute lymphoblastic 
leukemia (ALL) patients; and 6) a LASSO penalized regression model that predicted 
vincristine-induced neuropathy and relapse in ALL patients and provided the basis for a 
risk assessment of the population. Overall, results from this dissertation provide an 
improved understanding of treatment effect in patients with an assessment of PK/PD 
combined and with a risk evaluation of drug toxicity and efficacy.                                                          
 
Robert R Bies, Pharm.D., Ph.D. 
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CHAPTER I: Introduction 
1. The need for modeling and simulation in drug development   
         Despite significant expenditures, the drug development process requires a 
substantial amount of time and it is expensive and prone to failures. The average length 
of clinical development is quoted as 7-12 year at a cost of $0.8-1.7 billion per approved 
agent (Kaitin et al., 2010; Dimasi et al., 2001; Connolly et al., 2001; Lesko et al., 2004). 
The cost of drug development takes into account those compounds that undergo clinical 
testing but do not make it to the marketing approval or fail NDA approval. Therefore, the 
rate at which pharmaceutical firms successfully develop investigational compounds for 
marketing approval by regulatory agencies is a critical indicator of the effectiveness of 
the drug development process (DiMasi et al., 2010).  A retrospective analysis of both 
public and private drug pipeline database as well as from surveys comprising nearly 4000 
drugs and biologics from the 50 largest pharmaceutical firms between the mid-1990s and 
the early 2000s by DiMasi’s group pointed to clinical approval success rates that 
remained lower than 20% with an upward trend in costs (DiMasi et al., 2010).  Estimated 
clinical approval success rates differed significantly by therapeutic class; for example, in 
oncology, the success rate was only ~5% (Kola et al., 2004). Furthermore, even with the 
massive amount of data that are generated and obtained from the clinical trials every year, 
lots of useful knowledge and information remains undiscovered or underutilized (Ette et 
al., 2007). Processes and technological innovations that can improve the predictability of 
outcomes for new compounds can therefore significantly increase the productivity of new 
drug innovation (DiMasi et al., 2010). Indeed, in the white paper Challenge and 
Opportunity on the Critical Path to New Products published in March of 2004, the Food 
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and Drug Administration (FDA) has addressed this concern and states “Not enough 
applied scientific work has been done to create new tools to get fundamentally better 
answers about how the safety and effectiveness of new product that can be demonstrated 
in faster time frames, with more certainty, and at lower cost. A new product development 
toolkit—containing powerful new scientific and technical methods such as animal or 
computer-based predictive models, biomarkers for safety and effectiveness, and new 
clinical evaluation techniques—is urgently needed to improve predictability and 
efficiency along the critical path from laboratory concept to commercial product. We 
need superior product development science to address these challenges.” To highlight all 
these issues regarding the high attrition rates and increasing costs in drug development, 
model-based drug development has been proposed as one methodology to potentially 
make drug development more productive by assessing the ongoing clinical trial studies as 
well as historical drug databases using mathematical and statistical approaches to 
construct and utilize models to increase the understanding of the drug and disease.       
2. Model based drug development (pharmacometrics and statistics)                                  
         Model-based drug development (MBDD) is the concept of utilizing pharmaco-
statistical approaches to evaluate drug efficacy and safety from preclinical through the 
clinical data to improve drug development knowledge management and decision-making 
(Milligan et al., 2013; Lalonde et al., 2007). As Lalonde et al. described, the key 
components of MBDD can be divided into six categories: PK-PD and disease/placebo 
model; meta-analysis of candidate drug and competitor data, design considerations and 
trial execution models; data-analytic models; quantitative decision criteria; and trial 
performance metrics (Milligan et al., 2013; Lalonde et al., 2007).  Those principles can 
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potentially overcome the common limitation of the current drug development strategy, 
specifically, that prior information is partly or completely ignored when analyzing and 
interpreting the results of the most recent clinical trials.  
         One of the essential parts of MBDD is the discipline of pharmacometrics. 
Pharmacometrics has been described as “the science of developing and applying 
mathematical and statistical methods to  a) characterize, understand, and predict a drug’s  
pharmacokinetic and pharmacodynamic behavior, b) quantify uncertainty of information 
about that behavior and c) rationalize data-driven decision making in the drug 
development process and pharmacotherapy” (Ette et al., 2007). The modeling and 
simulation approach not only quantifies the exposure-response relationship, disease 
progression, and the level of variability, but also identifies the potential contributors to 
that variability. In addition, these models can be linked and applied to competing study 
designs and to customize patient drug therapy through therapeutic drug monitoring and 
improved population dosing strategies; therefore, facilitating the implementation of the 
personalized medicine (Bonate , 2011). The idea of personalized medicine can be further 
utilized to emphasize the significance of biomarker findings. As a result, biomarker 
identification and validation become one of the major foci of pharmacometricians across 
disciplines. Applying quantitative assessment approaches to understand biomarker 
dynamics can potentially: identify patients at risk for a disease; predict a patient response; 
and predict the risk of toxicity. 
         Other statistical tools have also become popular to describe the relationship of 
disease and clinical outcome which may or may not involve drugs or treatments using 
mathematical equations such as regression analysis and survival analysis. In particular, 
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survival analysis has been commonly used in clinical studies to analyze time to event data 
which can provide insight of patients’ efficacy and safety profiles and facilitate decision 
making such as dose selection or patient care.  
         Since the quantity of the data expands as the improvement of data collection 
method, an efficient computer tool becomes critical and demanded to facilitate the access 
to large amount of information (ex: pharmacogenomics profiles). This can be overcome 
by the development and implementation of bioinformatics tool. 
3. The opportunities (application) of modeling and simulation in drug development                              
         As the role of modeling and simulation in drug development becomes more 
significant, there are many opportunities available for modeling across different phase of 
studies. In the journal of the pharmaceutical sciences 2002, Meibohm and Derendorf 
initially indicated the potential modeling and simulation applications from the discovery 
and preclinical phase to clinical setting and even the post-marketing phase in Figure 1.1. 
As shown in Figure 1.1, in the early stages of drug development, modeling and 
simulation can explore the pharmacokinetic and pharmacodynamic of drug and drug-drug 
interaction in in vivo system and leverage the understanding of biomarker to evaluate 
drug efficacy and toxicity profile. It can also be useful in selecting dosage regimen or 
form based on the previously developed PK/PD relationship and integrate the early 
decision making in candidate selection. Furthermore, with the modeling assessment of 
preclinical studies, a first to human dose can be suggested by extrapolating from the in 
vivo model, and the translational approach can be also beneficial for systematically 
assessing some pharmacological relationships which have not been assessable in the 
human system.  A parallel approach has been suggested by combining preclinical and 
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early clinical development as a way to expand the learning process to all the phases of 
drug development. In the learning and confirming process of clinical trial, modeling and 
simulation serves as a tool to continuously evaluate exposure-response relationship across 
different therapeutic areas (Huang et al., 2013; Meibohm et al., 2001; Sheiner, 1997). The 
model can further evaluate contributors such as gender and food effects on exposure, 
predict PK/PD under a new dosing regimen, predict PK/PD in a special population such 
as children or elderly, and characterize drug-drug interaction and drug-disease interaction 
(Meibohm et al., 2002). In clinical drug development, predictive tools such as Monte 
Carlo simulation can explore various dosage regimens and optimize the trial design 
which might allow reducing the numbers and costs of the studies and improving drug 
development efficiency (Meibohm et al., 2002). 
 
Figure 1.1. Opportunities (applications) for modeling and simulation across the drug 
development process. (This figure is reproduced with permission of John Wiley & Sons, Inc. 
Meibohm B anad Derendorf H, Pharmcokinetic-pharmcodynamic studies in drug product 
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development, and copyright © 2002 Wiley-Liss, Inc. and the American Pharmaceutical 
Association). 
 
4. Type of models 
         As the demands and opportunities of modeling and simulation increases in each 
phase of drug development, various types of models have been advocated to address 
specific questions. Some of the model strategies are introduced in the following sections, 
and the applications are demonstrated in each section. 
4.1 Pharmacokinetic modeling 
         Pharmacokinetics began as a way to characterize the absorption, distribution, 
metabolism and elimination of a drug in the body and to reduce a concentration-time 
profile into a set of parameters that could be used for comparison, evaluation, and 
prediction (Teorell, 1937; Teorell 1937; Widmark, 1933; Wanger, 1973; Widmark, 1933; 
Derendorf et al., 2000). As the assays or the measurement tools becoming available not 
only in the plasma but also in some tissue levels, disposition of drug exposure pattern can 
be better understood. Furthermore, many forms of drug exposure were also characterized 
in the pharmacokinetic analysis. Depending on whether drug concentration measurements 
are available; sometimes, dose can be used as a representation of nominal exposure, and 
population average exposures after dose have been proposed. These are known as KPD 
models explore the dose-driven shape of the concentration vs time profile specifically the 
temporality without inter-individual variability in the context of exposure and 
pharmacodynamics relationship. Typically, drug concentrations measured in plasma 
represent the systemic exposure of the drug. Pharmacokinetic parameters such as 
clearance (CL), volume of distribution (Vd) or descriptors such as area under the curve 
(AUC), maximum concentration (Cmax) and elimination half–life (      can be derived 
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or calculated.  Beyond the drug concentrations measured in the biologic fluid, with the 
innovation and improvement of the measurement techniques, drug concentrations now 
can be measured at the target site using microdialysis or positron-emission tomography 
scan so that the responses can be more precisely correlated to drug concentrations at the 
effect site (Derendorf et al., 2000; Chefer et al., 2009; Jacobson et al., 2013). In addition, 
understanding the covariate effect on systematic exposure and variability associated with 
exposure is also an important component in a pharmacokinetic model. Covariates are 
characteristics describing the patients, the conditions of the drug treatment or other 
factors potentially influencing the outcome. In late 90’s, Vozeh’s and Grasela’s groups  
demonstrated how covariates can be used to predict patients’ pharmacokinetics through 
the covariate model development in a population analysis (Vozeh et al., 1982; Grasela et 
al., 1984; Grasela et al., 1985; Grasela et al., 1987). The covariates can be constant within 
an individual or time-varying.  They not only contribute to the estimates of structure 
model parameters but also impact the random effects distribution (Ribbing, 2007). In 
general, covariates can be classified as intrinsic factors (e.g. age, race, weight, sex, and 
genotype) or extrinsic factors (e.g. compliance, and smoking status) or can be categorized 
as categorical or continuous variables based on the measurement scale (Holford, 2013). 
In the process of model development, an assessment of covariate effect can improve 
predictive model performance for subject in the current data set, for trial simulation of 
future studies or for future patient population (Gastonguay MR, 2011). 
4.2. Pharmacodynamic modeling 
         Pharmacodynamics is often defined as what the drug does to the body (Ette et al., 
2007).  Based on the definition from Derendorf et al, “pharmacodynamics is a broad term 
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that is intended to include all of the pharmacological actions, pathophysiological effects 
and therapeutic responses, either beneficial or adverse of active drug ingredient, 
therapeutic moiety, and/or its metabolite(s) on the various systems of the body from 
subcellular effects to clinical outcomes” (Derendorf et al., 2000).  In pharmacodynamic 
modeling, the pharmacological action is often modeled as a time dependent effect that is 
related to drug exposure, and the endpoints of pharmacodynamics can be physiological 
changes such as blood pressure and cholesterol level or clinical outcomes such as 
survival or toxicity.  In addition, with the flexibility of mathematical functions, different 
types of pharmacodynamic endpoints including continuous, categorical, ordered 
categorical or count data can be described. Another type of pharmacodynamic response is 
the time to a specific event. A common approach for modeling, this type of event is 
survival analysis. Typically, a proportional hazard model or parametric survival model is 
likely to be used to describe the baseline hazard and the risk that depends on covariates in 
a predefined time period. 
4.3. Population PK/PD modeling 
         Sheiner and his colleagues published several articles illustrating a new 
mathematical approach to analyze pharmacokinetic data, which was later called 
population pharmacokinetics in the late 1970s and early 1980s (Sheiner et al., 1977; 
Sheiner et al., 1980; Sheiner et al., 1981; Sheiner et al., 1982; Bonate , 2005). In one of 
the Sheiner’s publications, he demonstrated that less-biased estimates of the population 
means and variances were found using the population approach than either the naïve-
pooled or 2-stage approach (Sheiner et al., 1981; Bonate, 2005). Population methods 
were further applied to assess pharmacodynamics endpoints. Population PK/PD modeling 
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approaches represent a methodology of leveraging sparse PK and PD data. Commonly, 
this approach is applied to relatively sparse sampling but in a sufficient number of 
individuals so that inter-individual variability can be assessed and allows integrating data 
from single or multiple studies as well as studies from different phases (Ette et al., 2007; 
Gross et al., 2000). With the flexibility of analyzing combined data from different studies, 
PK or PD profile of the population can be better represented. However, analyzing 
combined data in a typical model-based metal-analysis may potentially result in bias 
estimates of parameters. Therefore, this strategy should be carefully evaluated and 
applied (Gastonguay et al., 2005; Gastonguay et al., 1999). This strategy also allows for 
the identification and quantification of the sources of inter-individual variability in 
response such as genetic polymorphisms in metabolic enzyme or transporter, clinical and 
demographic factors. In particular, the population modeling approach has become one of 
the standard assessments of clinical drug development that regulatory agencies 
recommend (Department of Health and Human Services, 1999).  
4.4. Biomarker modeling 
         The official National Institutes of Health (NIH) definition of a biological marker 
(Biomarker) is “a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention.”  This definition is broad and though not explicitly stated, 
includes laboratory tests, radiologic studies as well as physical exam findings. Although 
biomarker is a relatively new term that dates back to the late 1960s, biologic assessments 
and measurements in the evaluation of human disease were practiced in antiquity 
(Ferguson et al., 2010). Clinically useful biomarkers have evolved over time and play an 
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increasingly important role in many aspects of pharmaceutical discovery and 
development including personalized medicine and the assessment of safety profile, 
reflecting the scientific and technologic progress made over the centuries.   
         As a result, an increasing number of clinically relevant tests and procedures are 
available to estimate organ injury and guide treatment. Recent discoveries in genetics and 
molecular biology have resulted in impressive advances in our understanding of the 
pathophysiologic processes of individual disease and yielded an abundance of 
prospective therapies directed against novel targets (Ferguson et al., 2010).  This has 
brought about an increased focus on biomarker identification, validation, and 
quantification, as well as the development of analytical technologies for biomarker 
measurement. Efforts at biomarker discovery and validation have intensified since the 
twenty-first century (Ferguson et al., 2010).  Advanced genomic, proteomic, and 
metabolomics techniques now permit comparative analysis of specimens from healthy 
and diseased individuals, facilitating biomarker identification. Generally, there are four 
types of biomarker endpoints (Figure 1.2) (Jenkins et al., 2011). The first is called a 
prognostic endpoint which is used to predict the likely disease prognosis independent of 
the mode of treatment. For instance, the number of circulating tumor cells (CTCs) in 
peripheral blood at baseline can give an indication of survival prognosis in prostate 
cancer (De Bono et al., 2008).  The second type is a predictive biomarker that predicts the 
likelihood of response to a particular treatment or a class of treatments.  As an illustration, 
CTCs can also be a predictive biomarker when compared wild type patients vs. patients 
with mutation in the same treatment. This acts more like a covariate to explain the 
variation in the outcome. The third type of biomarker is a pharmacodynamics biomarker.  
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The definition of a pharmacodynamic biomarker is a response over time to a treatment 
intervention. Simple biomarker examples include cancer antigen 125 for ovarian cancer 
(Schmidt et al., 2011) and PSA for prostate cancer (Romero et al., 2013), and tracking 
treatment over time is an important component. Pharmacodynamic biomarkers could 
reflect the safety and/or efficacy of a treatment and are typically measured at multiple 
time points. Markers that correlate well with a widely accepted clinical outcome at both 
an individual and group level could potentially act as a surrogate endpoint and substitute 
for a recognized clinical endpoint (Katz et al., 2004; Rothmann et al., 2012) and are the 
fourth type of biomarker. For example, LDL cholesterol can act as a surrogate for major 
cardiovascular events in the licensing of statins (Tardif et al., 2006). The model based 
assessment of the dynamics of a biomarker can provide insight into the disease 
progression and capture a therapeutic drug effect which might be useful for early decision 
making before the clinical endpoints are available. 
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Figure 1.2. Biomarker endpoint types (This figure is reproduced with permission of John Wiley 
& Sons, Inc. Jenkins et al., A statistician’s perspective on biomarkers in drug development, and 
copyright © 2011 John Wiley & Sons, Ltd.). 
                                                                                                                                                                  
4.5. Clinical Trial simulation 
         Another significant component of pharmacometrics is stochastic simulation. 
Simulation has been widely used in many disciplines such as engineering before being 
used in drug development. It can serve not only as a predictive tool to evaluate the 
proposed trial design and the outcome under certain assumptions and to exposure pattern 
resulting from various dosage regimens, sampling schemas and population characters but 
also as an analytical tool to characterize exposure-response relationship in different 
modeling circumstances in a virtual population (Kimko et al., 2002; Kimko et al., 2011; 
Meibohm et al., 2002). Clinical trial simulation also allows us to compare different study 
designs and optimize study design by updating the design continuously. With the 
simulation assessment, the drug development process can be more efficient and powerful 
and more informative in bridging studies from one phase to another. 
4.6. Time to event model (GWAS study) 
         Clinical trials are often performed to evaluate the efficacy of new treatment 
regimens and the efficacy of existing treatments in a special population (National cancer 
institute, 2011). As mentioned briefly in section 4.2, the efficacy endpoints of the clinical 
trials are primary described as an event of interest such as death, relapse, and adverse 
drug reaction (Crom et al., 1994). The follow-up time of the patients may vary depending 
on the disease and treatment, the time component is an important assessment to 
understand the event occurrence. These statistical models consider the time course until 
an event occurs and compare the cumulative probability of events over time for two or 
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more cohorts (Lee et al., 1982; Singh et al., 2011). Therefore, a statistical procedure 
which is likely to applied for analyzing this endpoints is called time to event analysis. 
Because survival is one of the most common endpoints in time to event analysis, people 
also describe this type of analysis as survival analysis. In time to event analysis, one of 
the essential components is how the dichotomous event of interest is pre-defined. For 
example, if an adverse drug reaction is classified using a grading scale from 0 to 5, the 
event of interest can be specified as binary or categorical outcome based on the question 
we are interested in (National cancer institute, 2009). Another key component of most 
time to event model is censoring. Censoring can arise under three circumstances: when an 
individual does not experience the event during the study period; when an individual 
discontinues the follow-up during the study period; and when an individual drops out 
from the study due to other events (Singh et al., 2011).   
         One of the most common time to event model is the Cox proportional hazards 
model (Cox et al., 1972). This model was first introduced by Cox, in 1972, for analysis of 
survival data with and without censoring, and for identifying the contributors to the 
difference of survival in clinical trials. These contributors include treatment effect, 
prognostic and clinical covariates. Different from parametric survival or the Kaplan-
Meier method (Itman et al., 1992), the Cox regression model is considered a semi-
parametric method which does not require a pre-specified hazard function for the baseline 
hazard but considers the hazard to be proportional at any point in time for the 
characteristics based on the model assumption. The hazard is calculated using the 
equation shown below: 
 
 
H(t = H (t  x exp(b X + b X + b X +  + b X ) 
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where X1 ... Xj represent a group of predictor variables, and H0(t) is the baseline hazard at 
time t, representing the hazard for a person when all the predictor variables are 0 (Cox et 
al., 1972). 
The Cox model has been widely used in covariate selection for association studies such 
as Genome wide association study (GWAS), and it is very useful and robust tool in 
clinical research and provides valuable information about an intervention.  
5. Hypothesis and specific aims 
         Modeling and simulation has been shown to be a critical tool in drug development 
and patient care. In drug development, modeling and simulation provides an early 
assessment of a new drug entity in the initial discovery phase to facilitate: the compound 
selection; the prediction of pharmacokinetic-pharmacodynamic(PK-PD) relationships 
from in-vivo animal results to human; the characterization of exposure-response profiles 
at both the individual and population levels in the clinical studies; the evaluation of the 
trial design; and insights to inform decision making in drug development. Furthermore, as 
the studies go beyond drug approval, modeling and simulation can also be applied to the 
post-marketing evaluations for special populations and to predict drug toxicity and 
efficacy in a long-term patient care setting with the potential to inform clinical 
recommendations.   
         The main objectives of this proposal use a modeling and simulation approach: 1) to 
leverage our understanding of PK/PD relationship from pre-clinical system to human; 2) 
to quantitatively understand the drug impact on patients; 3) to evaluate clinical trial 
deigns and; 4) to identify potential contributors (predictors) to drug toxicity and efficacy. 
This work explores the hypothesis that modeling and simulation can be useful to provide 
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insight into trial designs and facilitate decision making (Steimer et al., 2000). To test this 
hypothesis, we proposed the following specific aims:  
1. Build a population pharmacokinetic model that accounts for both plasma and brain 
concentrations measured in rats and utilize this model to predict human concentrations of 
clozapine and its N-desmethyl metabolite, norclozapine. (Preclinical PK model) 
2. Identify covariates that contribute to variability in sertraline concentration by 
performing a population pharamcoknetic analysis of sertraline in elderly patients with 
Alzheimer disease and generating population pharmacokinetic parameters for this 
population. (Population PK model in a special population) 
3. Assess and refine the published FDA longitudinal tumor size model for predicting 
survival in NSCLC patients using archived tumor measurement data. (Pharmacodynamic 
/Biomarker model)   
4. Evaluate whether a pre-defined oncology trial with a sparse drug concentration 
sampling schedule can adequately capture individual level drug exposures, random 
variability and the food effects of abiraterone and nilotinib. (Clinical trial simulation and 
trial design evaluation) 
5. Establish a candidate gene database which included those polymorphisms associated 
with vincristine-induced neurotoxicity in childhood ALL patients from the GWAS study 
and gene enrichment analysis (Time to event model) 
6. Create a signature comprising a combination of genetic and clinical markers that 
predict vincristine-induced neurotoxicity and relapse in childhood ALL patients using 
LASSO penalized regression model. (Signature model) 
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          Successful completion of these aims would result in accelerated and information 
rich decision making by leveraging data from previous trials to simulate clinical 
outcomes as well as aid in the design of future clinical trials. Modeling and simulation 
allows one to explore the pharmacokinetic profile in a special population and exposure 
and response relationship in preclinical and clinical setting to facilitate drug development 
as well as optimal drug utilization and therefore provide better care for the patients. 
Furthermore, potential biomarkers for survival prediction and drug- induced adverse 
reactions identified by the modeling approach can help in guiding treatment decisions and 
facilitating the future protection for patients. Ideally, patients most likely to derive a 
benefit from treatment are more likely to be targeted; in contrast, those patients identified 
as non-responders are more likely to be excluded so that unnecessary harm to patients can 
be minimized.  This may allow for the identification of ineffective treatments earlier in 
the clinical trial process thus also avoiding unnecessary patient exposures. In this study, 
modeling and simulation demonstrates the potential applications in drug development and 
patient care and the utility of clinical prediction. 
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CHAPTER II: Preclinical model-prediction of brain clozapine and norclozapine 
concentrations in humans using a scaled pharmacokinetic model for rat brain and 
plasma pharmacokinetics (Published in Journal of translational medicine with open 
access license http://www.biomedcentral.com/about/license) (This material is reproduced 
with permission of BioMed Central) 
1. Introduction       
         Schizophrenia is a debilitating disorder that affects approximately 1% of the global 
population without regard to race, sex or socioeconomic status (Mathers et al., 2006). It 
typically strikes in the late-teen years or early twenties and is characterized by a high rate 
of morbidity and mortality. Given these high personal and societal costs, investment in 
research aimed at understanding the biology of the disease, its genetic components and 
their interplay with environmental factors, continues on many levels. Over the past 50 
years, pharmacotherapeutic support has been instrumental in managing primarily the 
positive symptoms of the disease and hinges on suppression of a central circuitry 
dysfunction that can be normalized by antagonism of dopamine D2 receptors in the 
striatum (Murray et al., 2008). Introduction of clozapine, the first so-called atypical 
antipsychotic approximately 25 years ago, represented a significant advance in our 
understanding of schizophrenia from a systems biology perspective in that this drug did 
not have the typical side effects of the 1
st
 generation neuroleptics. This reduction in side 
effects was attributed to higher 5HT-2A than D2 binding (Meltzer et al., 1989).   
         However, clozapine pharmacology is not limited to D2 and 5HT2A antagonism. 
Albeit unintentionally, the drug binds to several other dopamine and serotonin receptor 
subtypes, as well as to muscarinic M1/M4 and alpha-1 adrenergic receptors with 
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pharmacologically relevant affinity (Horacek et al., 2006). From a clinical perspective, 
this broad receptor coverage may account for clozapine’s unique superiority in treatment 
resistant schizophrenia (TRS), even amongst other atypical antipsychotics. From a 
research perspective, the broad receptor coverage of clozapine conceivably makes the 
drug a useful tool to advance our understanding of complex pharmacotherapy that 
incorporates multiple interacting receptor systems.  
          The use of positron emission tomography (PET) imaging to measure receptor 
occupancy of clozapine and other atypical antipsychotics in humans has been invaluable 
in demonstrating the importance of D2 and 5HT2A receptor antagonism contributing to 
the efficacy of these drugs (Takeuchi et al., 2013; Moriguchi et al., 2013; Tsuboi et al., 
2013). However, broader application of this non-invasive technique has been limited by 
the lack of ligands specific for other receptors to which clozapine has affinity. In this 
regard, availability of other approaches that are complementary to PET imaging would be 
useful. One possibility is to link non-clinical measurements of clozapine disposition in 
the brain with clinical studies of clozapine systemic exposure using a translational PK 
modeling approach.  Prediction of clozapine CNS exposure could then be related to its 
receptor binding kinetics at multiple receptors to impart a virtual predicted 
pharmacodynamic component to a model. This approach has been used recently to 
predict CNS concentrations of atomoxetine and duloxetine that were in the range of 
receptor affinities associated with therapeutic doses (Kielbasa et al., 2012). In a related 
manner, a population pharmacokinetic-pharmacodynamic (PK-PD) modeling approach 
was used to predict D2 receptor occupancy of olanzapine in humans (Johnson et al., 
2011), and the D2 and 5HT2A receptor occupancy of risperidone and its active 
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metabolite paliperidone (9-OH risperidone) (Takeuchi et al., 2013; Moriguchi et al., 2013; 
Tsuboi et al., 2013; Kozleiska et al., 2012). These studies, as well as earlier PK-PD 
models applied to other CNS drugs (de Lange et al., 2012; de Lange et al., 2005), provide 
confidence in the ability of this approach to deepen our understanding of drug action in 
human brain.   
         A recent study measured clozapine and its N-desmethyl metabolite, norclozapine,  
in extracellular fluid (ECF) of rat medial prefrontal cortex using quantitative 
microdialysis, and these results provided evidence of net efflux from brain across the 
blood-brain barrier (BBB) (Cremers et al., 2012). This suggests that plasma 
concentrations may not be a good predictor of brain concentration for clozapine or 
norclozpaine. Therefore, prediction of clozapine exposure in the ECF of human brain 
using a translational PK modeling approach could be cross-validated against PET results 
at D2 and 5HT2A receptor occupancy in humans, and subsequently used to estimate 
clozapine receptor occupancy at the drug’s other receptor targets for which PET tracers 
do not exist.  Such comprehensive PK-PD model could potentially support individualized 
dosing of clozapine to improve its efficacy and CNS tolerability. It would also support 
research aimed at discovering new approaches for the treatment of the schizophrenia in 
its different forms.    
         The purpose of this study was; (1) to build a PK model that accounted for both 
plasma and brain concentrations measured in rats; (2) to utilize this model to predict 
concentrations of clozapine and norclozapine in human brain. This would allow for the 
prediction of expected receptor occupancy in humans. 
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2. Materials and Methods 
2.1. Study Design     
         A single dose of clozapine (10mg/kg) was administered subcutaneously to four 
male Wistar rats with an average weight of 0.35 kg purchased from Harlan (Zeist, The 
Netherlands). Three days prior to administration a microdialysis guide cannula was 
surgically implanted in the medial prefrontal cortex; at the same time, a catheter for blood 
sample collection was placed in the right jugular vein and was exteriorized through an 
incision at the top of the head.  This vascular cannulation enabled an equivalent volume 
of saline replacement for each blood sample.  A MetaQuant probe (6 mm, cellulose 
membrane, BrainLink, The Netherlands) was inserted into the guide cannula 24 hours 
prior to drug administration to enable sampling of brain extracellular fluid (ECF).  
Concentrations of clozapine and norclozapine were measured in plasma and brain (ECF) 
by HPLC with tandem mass spectrometry in the positive ion mode as previously 
described (Cremers et al., 2012). For each rat, the unbound concentrations in each 
compartment were measured at 9 time points (0, 15, 30, 60, 90, 120, 240, 360 and 480 
minutes) in plasma and 18 time points (-30, 0, 30, 60, 90, 120, 150, 180, 210, 240, 270, 
300, 330, 360, 390, 420, 450 and 480 minutes) in brain. A single dose of norclozapine 
(10 mg/kg) was also administered subcutaneously to another five male Wistar rats with 
an average weight of 0.34 kg bought from the same Harlan laboratories. Concentrations 
were measured in plasma and brain ECF, and the same time points were used as those 
specified for clozapine.   
 
 
                                                                          21 
 
2.2. Model Development  
         Different model structures were initially evaluated using the system dynamics 
software VENSIM (Ventana Systems, Inc., MA, US). Thereafter a population approach 
was used to describe the pharmacokinetics of clozapine and norclozapine. Population PK 
parameters were estimated using a nonlinear mixed effect modeling approach, as 
implemented in NONMEM version 7.2 (Icon Development Solutions, Hanover, 
Maryland) using Wings for NONMEM version 7 (Holford, 2013). The first-order 
conditional estimation method (FOCE) with interaction was used to estimate the 
structural PK parameters and the random effects parameters.   
         Model development was started with an assessment of clozapine PK in plasma.  
One and two compartment models with first order absorption for clozapine in plasma 
were tested. A peripheral compartment structure was subsequently implemented to 
represent the brain extracellular fluid concentrations. The transfer characteristics of 
clozapine between the plasma and the brain compartment were evaluated using an 
intercompartmental clearance, CLin/CLout, as well as incorporating delay functions 
(Savic et al., 2007). These delay functions included a lag time and transit compartment 
approaches.  Once the structural model for clozapine was established, the plasma 
compartment of norclozapine was integrated and then connected to the brain 
compartment. The same strategy was utilized in building the structural model for 
norclozapine concentrations that were measured following norclozapine administration. 
Clozapine and norclozapine concentration measurements were then combined from the 9 
rats and modeled simultaneously in the final structural model. The volume of distribution 
of clozapine and norclozapine in brain were tested with and without fixing this parameter 
                                                                          22 
 
to a literature reported value (Fridén et al., 2007). A parallel metabolic pathway from the 
extravascular space was also explored.  
         Between-animal variability (BAV) for PK parameters was assumed to be log-
normally distributed and evaluated using an exponential model Pi = PTV x e
ηp
 where Pi is 
the parameter estimate for the i
th
 animal, and PTV is the typical parameter value at the 
population level. The difference between i
th
 individual and population parameter values 
was described by p, which was identically distributed with mean equal to 0 and variance,  
ωη
2
 (Feng et al., 2006).  A combined additive and proportional model was first used to 
describe the intra-animal variability. If one of the elements of the model was found to be 
negligible and not significant, it was then removed from the residual error model. 
Residual error parameters were assumed to be normally distributed with mean equal to 0 
and variance, 2.  
2.3 Model selection and evaluation  
         Model evaluation was based on a likelihood ratio test using the objective function 
value (OFV) provided by NONMEM. The minimum OFV returned by NONMEM is 
approximately equal to −2 × log likelihood (−2LL) and served as a guide during model 
design. A decrease in −2LL of 6.63 points for 1 degree of freedom was regarded as a 
significant model improvement, corresponding to a p value of 0.01 for nested models. 
The final model was further examined using goodness-of-fit plots generated using R 
version 2.13 based on the conditional weighted residuals distribution and the predicted 
versus observed concentrations at both the population and individual levels. Furthermore, 
the final pharmacokinetic model was also evaluated using a visual predictive check 
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(VPC), and the uncertainty on each parameter was determined using a non-parametric 
bootstrap sampling with replacement 1000 times from the original dataset. 
2.4 Prediction of Human Clozapine, Norclozapine Brain Concentrations and 
Expected Receptor Occupancy  
         After the pharmacokinetic model of clozapine in rat was finalized, the PK model 
framework was adapted by scaling PK parameters with allometric principles to predict 
human concentrations in brain. The following exponents were utilized scaling body 
weight to: clearance 0.75; volume of distribution 1; and first order rate constants 0.25 
(Sharma et al., 2009). A 50% of conversion from clozapine to norclozapine in humans 
was assumed in the model based on prior reports (Centorrino et al., 1994; Raedler et al., 
2008; Couchman et al., 2010), and this was implemented in the simulated model 
assuming CLclo/F is equal to CLclo-p/F. The model performance was evaluated comparing 
model simulated plasma concentrations to published human clozapine concentrations 
(Ismail et al., 2012) in plasma at steady state following 200, 300 and 400 mg daily doses. 
The published human clozapine data were reported as total concentrations, and these 
concentrations were converted to free concentration using 3% unbound fraction 
(Clozapine Product Insert, 2013) prior to the comparison. After model validation, the 
simulated human clozapine and norclozapine concentrations were used to calculate the 
expected human receptor occupancy for multiple receptors.  Receptor occupancies were 
predicted for: dopamine 2(D2); serotonin 2A (5-HT2A); muscarinic-1 (M1); alpha-1 
adrenergic (α1); alpha-2 adrenergic (α2); and histamine-1 (H1) using published 
equilibrium dissociation constants (Kd) for clozapine (Seeman et al., 2002: Bumaster et 
al., 1996; Kroeze et al., 2003) and norclozapine (D2 only) (Lidow et al., 2000). 
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3. Results 
3.1 Rat Population Pharmacokinetics 
         A two-compartment model with first order absorption best described clozapine 
pharmacokinetics in rats using a central compartment for plasma concentrations and a 
peripheral compartment for brain concentrations.  Between plasma and brain, an apparent 
delay in the distribution of clozapine was identified.  Several structural models were 
tested to capture the observed delay. A transit compartment model with two 
compartments best described flow from plasma to brain, and inter-compartment clearance 
described the return from brain to plasma (Figure 2.1). Population pharmacokinetic 
estimates are given in Table 1. Norclozapine exposures in plasma and brain following 
clozapine administration were adequately described using a similar structure, but with 
one fewer transit compartment (Ktr2), which was estimated to be approximately 40% of 
the clozapine value. The volume of distribution of clozapine (Vclo-p/F) and norclozapine 
in brain (Vmet-p/F) were fixed to the previously estimated values in the final model. 
 
Although a significant reduction in the OFV was observed when both parameters were 
estimated, they were estimated with very poor precision. The elimination of clozapine 
converted to norclozapine was CLclo-met at 0.055 L/min, which is approximately 10% of 
total clozapine systemic clearance. The NONMEM control stream with the selected 
model is also included in the supplementary material (Additional file 1). 
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Figure 2.1. Compartmental representation of clozapine and norclozapine pharmacokinetics. 
Two compartments in blue represented the plasma and brain compartment of clozapine. 
Two compartments in green represented the plasma and brain compartment of norclozapine. 
Clo (Clozapine): CLclo /F=clearance of clozapine; Vclo-p /F=volume of distribution of clozapine in 
plasma; Kaclo =absorption rate of clozapine; Qclo /F=intercompartmental clearance of clozapine;  
Vclo-b /F= volume of distribution of clozapine in brain; Ktr1= transit rate constant of clozapine.  
Met (Norclozapine): CLclo-met /F=clearance of clozapine to norclozapine; CLmet /F=clearance of 
norclozapine; Vmet-p /F=volume of distribution of norclozapine in plasma; Kamet =absorption rate 
of norclozapine; Qmet /F=intercompartmental clearance of norclozapine;  
Vmet-b /F= volume of distribution of norclozapine in brain; Ktr2= transit rate constant of 
norclozapine.  
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         Bootstrap analysis  Median [5-95th percentiles] 
Parameters Estimates (RSE%) BAV (RSE%)                 Estimates                                                    BAV   
Clozapine         
CLclo/F (L/min) 0.5(20.3) 
 
         0.463[0.358-0.661] 
 
Vclo-p/F (L) 19.4(40.3)  
           18.9[5.43-31.59] 
 
Kaclo (1/min) 0.00801(14.7)  
0.00815[0.0051-0.0095] 
 
Qclo/F (L/min) 2.01(40.8) 0.193(33.6) 2.08[0.58-3.43] 0.2[0.07-0.29] 
Vclo-b/F (L) 0.214 FIXED  
 
 
Ktr1 (1/min) 0.0125(9.4) 0.05 (48.9) 0.0129[0.011-0.015] 0.047[0.0033-0.069] 
Fclo  1 FIXED 0.259(37.1)  
0.243[0.062-0.35] 
Norclozapine 
    
Clclo-met/F 
(L/min) 
0.055(24.8) 
 
0.0584[0.04-0.0855] 
 
CLmet/F (L/min) 0.419(18.8) 0.111(74.8) 0.43[0.33-0.61] 0.08[0.0038-0.18] 
Vmet-p/F (L) 2.95(38.6) 0.168(51.1) 3.02[1.91-5.55] 0.149[0.000047-0.27] 
Kamet   (1/min) 0.00277(31) 0.371(44.2) 0.00296[0.0015-0.0047] 0.319[0.065-0.54] 
Qmet/F (L/min) 0.388(45)  
0.386[0.229-0.768] 
 
Vmet-b/F (L) 0.25 FIXED   
 
Ktr2 (1/min) 0.00517(12.3) 
 
0.00521[0.0045-0.0064] 
 
Fmet 1 FIXED   
 
Residual error 
(proportional) 
    
Parent-plasma 0.109(70) 
 
0.084[0.029-0.19] 
 
Parent-brain 0.0367(27) 
 
0.0371[0.023-0.055] 
 
Metabolite-
plasma 
0.0762(24.1) 
 
0.0714[0.051-0.11] 
 Metabolite-
brain 
0.014(18)   0.0133[0.0095-0.017]    
 
Table 2.1. Parameter estimates of final population pharmacokinetic model. 
Clo (Clozapine): CLclo /F=clearance of clozapine; Vclo-p /F=volume of distribution of clozapine in 
plasma; Kaclo =absorption rate of clozapine; Qclo /F=intercompartmental clearance of clozapine;  
Vclo-b /F= volume of distribution of clozapine in brain; Ktr1= transit rate constant of clozapine.  
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Met (Norclozapine): CLclo-met /F=clearance of clozapine to norclozapine; CLmet /F=clearance of 
norclozapine; Vmet-p /F=volume of distribution of norclozapine in plasma; Kamet =absorption rate 
of norclozapine; Qmet /F=intercompartmental clearance of norclozapine;  
Vmet-b /F= volume of distribution of norclozapine in brain; Ktr2= transit rate constant of 
norclozapine.  
BAV=between animal variability 
RSE%= percent relative standard error 
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Additional file1: NONMEM control stream 
… 
$SUBS ADVAN13 TOL=6 
$MODEL  
       COMP(DEPOT)        ; ORAL DOSE OF CLOZAPINE 
       COMP(CENTRAL)    ; PLASMA COMPARTMENT FOR CLOZAPINE 
       COMP(PER)              ; BRAIN COMPARTMENT FOR CLOZAPINE       
       COMP(TRANSIT1)   ; TRANSIT COMPARMENT 1 FOR CLOZAPINE  
       COMP(TRANSIT2)   ; TRANSIT COMPARMENT 2 FOR CLOZAPINE 
       COMP(MET)            ; PLASMA COMPARMANET FOR  NORCLOZAPINE  
       COMP(DEPOT2)      ; ORAL DOSE OF NORCLOZAPINE 
       COMP(PER2)            ; BRAIN COMPARMENT FOR  NORCLOZAPINE 
       COMP(TRANSIT3)   ; TRANSIT COMPARMENT 1 FOR NORCLOZPAINE 
    
$PK 
CLclo=THETA(1) 
CLclo-met=THETA(2)                               
Vclo-p=THETA(3)                              
KAclo=THETA(4)                          
S2=Vclo-p  
Vclo-b=THETA(5)                          
Qclo=THETA(6)*EXP(ETA(1))  
Fclo=THETA(7)*EXP(ETA(2))   
KTR1=THETA(8)*EXP(ETA(3))  
CLmet-p=THETA(9)*EXP(ETA(4)) 
KAmet=THETA(10)*EXP(ETA(5)) 
Vmet-p=THETA(11)*EXP(ETA(6)) 
Vmet-b=THETA(12) 
Qmet=THETA(13) 
KTR2=THETA(14) 
Fmet=THETA(15) 
 
 A_0(1)=0 
 A_0(2)=0 
 A_0(3)=0 
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 A_0(4)=0 
 A_0(5)=0 
 A_0(6)=0 
 A_0(7)=0 
 A_0(8)=0 
 A_0(9)=0 
 
;------------------------------------------------------------------------------------------ 
$DES 
;--------------------------------PK ODES ----------------------------------- 
DADT(1)=-KAclo*A(1) 
DADT(2)=KAclo*A(1)-(CLclo-met/Vclo-p)*A(2)-(CLclo/Vclo-p)*A(2)+(Qclo/Vclo-b)*A(3)-KTR1*A(2) 
DADT(3)=KTR1*A(5)-(Qclo/Vclo-b)*A(3) 
DADT(4)=KTR1*A(2)-KTR1*A(4)  
DADT(5)=KTR1*A(4)-KTR1*A(5)  
DADT(6)=(CLclo-met/Vclo-p)*A(2)-(CLmet/Vmet-p)*A(6)+KAmet*A(7)+(Qmet/Vmet-b)*A(8)-KTR2*A(6) 
DADT(7)=-KAmet*A(7) 
DADT(8)=KTR2*A(9)-(Qmet/Vmet-b)*A(8) 
DADT(9)=KTR2*A(6)-KTR2*A(9) 
… 
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         Figures 2.2 and 2.3 show the goodness of fit plots of the final model for the parent 
drug and metabolite in plasma and brain, respectively.  Population and individual 
predictions as well as the conditional weighted residuals distribution are shown in these 
figures. In the case of norclozapine, imprecision in population predicted plasma 
concentrations was evident and is attributed to the inter-animal variability observed in the 
context of the limited number of animals available to support these predictions. The 
majority of the fixed effects were estimated with less than 40% relative standard error 
(Table 1). BAV was estimated for several of the structural parameters and ranged from 
5% (Ktr1) to 75% (Clmet). Residual variability for clozapine in plasma and brain were 
10.9% and 3.7%, respectively, and residual variability of norclozapine in plasma and 
brain were 7.6% and 1.4%, respectively. VPC results are shown in Figures 2.4 and 2.5, 
the observed medians (dashed black lines) concentrations were adequately captured by 
the corresponding simulation based 90% predicted intervals of median concentrations for 
clozapine and norclozapine (shaded areas). Median, 5
 th
 and 95
th
 percentiles of the 
parameters derived from the bootstrap analysis of 1000 replicates are shown in Table 2.1.    
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Figure 2.2. Model diagnostic plots for clozapine.                                                                                                 
A and E: population prediction vs. observation plots for clozapine in plasma and brain ECF, 
respectively, solid line is line of identity.  B and F: individual prediction vs. observation plots for 
clozapine in plasma and brain ECF, respectively.  C and G: conditional weighted residuals vs. 
time for clozapine in plasma and brain ECF, respectively. D and H: conditional weighted 
residuals vs. population prediction for clozapine in plasma and brain ECF, respectively.  
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Figure 2.3. Model diagnostic plots for norclozapine.  
A and E: population prediction vs. observation plots for norclozapine in plasma and brain ECF, 
respectively, dashed line is the line of identity.  B and F: individual prediction vs. observation 
plots for norclozapine in plasma and brain ECF, respectively.  C and G: conditional weighted 
residuals vs. time for norclozapine in plasma and brain ECF, respectively. D and H: conditional 
weighted residuals vs. population prediction for norclozapine in plasma and brain ECF, 
respectively. 
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Figure 2.4. Visual predictive checks of clozapine in plasma and brain and norclozapine in 
plasma. 
Visual predictive check of clozapine concentrations in plasma (A) and brain (B), and 
norclozapine concentrations in plasma (C) following a 10 mg/kg subcutaneous dose of clozapine.  
Norclozapine concentrations in brain following a 10 mg/kg subcutaneous dose of clozapine were 
not measureable. 
Dashed line is the median of observed concentrations, the shape represents the 90% predicted 
interval of the median, and the dots represent the observed concentrations. 
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Figure 2.5. Visual predictive checks of norclozapine in plasma and brain. 
Visual predictive check of norclozapine concentrations in plasma (A) and brain (B) following a 
10 mg/kg subcutaneous dose of norclozapine.  
Dashed line is the median of observed concentrations, the shape represents the 90% predicted 
interval of the median, and the dots represent the observed concentrations. 
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3.2 Human PK Simulation 
         Simulated unbound clozapine concentrations in plasma from 12 to 24 hours after 
administration were compared with published human data and are shown in Figures 2.6A, 
2.6B and 2.6C for 3 doses (200, 300 and 400mg/day). Predicted occupancy of D2, 5-
HT2A, M1, α1, α2 and H1 receptors were calculated using simulated unbound clozapine 
and norclozapine (D2 only) brain concentrations for the three dose levels. For clozapine, 
the predicted median percentage of receptor occupancy of D2 ranged from 6-42%, 9-52% 
and 11-59% for the 200, 300 and 400mg daily doses, respectively, across the inter-dose 
time interval. The median percentage of 5-HT2A receptor occupancy decreased from 
93% to 52%, 95% to 62% and 96% to 69% from 6 to 24 hours after 200,300 and 400mg 
daily doses, respectively. For M1, α1 and H1 receptors, occupancies ranged from 74 to 
99% across the dosage interval. In addition, the median percentage occupancy of α2 
receptors was predicted to be in the range of 3-40% across the dosage interval.  For 
norclozapine, the predicted median percentage of receptor occupancy of D2 ranged from 
1.1-17.3% across the dosage interval. Receptor occupa 
ncy results across the dosage interval are summarized in Figure 2.7.  
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Figure 2.6. Simulated clozapine human unbound concentrations vs. published human 
concentrations at steady state in brain with 200,300 and 400 mg OID from 12 to 24 hours. 
The shape represents the 90% predicted interval of the median and the dots represent the 
observed data. 
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Figure 2.7. The predicted median percentage of receptor occupancy of D2, 5-HT2A, M1, α1, 
α2 and H1 for clozapine and D2 for norclozapine. 
The predicted median percentage of receptor occupancy of D2, 5-HT2A, M1, α1, α2 and H1 for 
clozapine were shown in A to F, respectively, and predicted median percentage of receptor 
occupancy of D2 for norclozapine was shown in G between 6 to 24 hour after dose. The solid 
line,dash line and dot line represent the predicted median percentage of receptor occupancy 
following 200, 300 and 400 mg daily doses, respectively. 
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4. Discussion 
         The model presented represents a unique PK model developed from directly 
measured concentrations of clozapine and norclozapine in rat plasma and brain ECF.  A 
multiple transit compartment model was used to account for a delay in the transport of 
clozapine and norclozapine from plasma to brain across the rat blood brain barrier.  Some 
evidence suggests that Pgp may be involved in the process of clozapine transport 
(Cremers et al., 2012; Doran et al., 2005) across the blood brain barrier. The need to 
incorporate transit compartments in the present model is consistent with a Pgp role in 
clozapine transport across this barrier. Using an animal model, drug exposure can be 
measured by microdialysis at the target site.    Based on a previously published non-
compartmental analysis, the ratio of AUC between parent and metabolite in the rat 
indicated that only about 10% of parent drug was eliminated through metabolism (Olsen 
et al., 2008). This is consistent with the ratio of norclozapine to clozapine clearance (Clclo-
met is 9.91% of Clclo.)  As the results revealed, even with relatively rich sampling profiles, 
the uncertainty of some parameters, in particular of between-animal variability, was large 
likely because of the small number of animals in this study.  
         Simulated human plasma concentrations were based on previously published human 
plasma concentration data (Ismail et al., 2012). The unbound plasma concentrations at 
steady state after a range of doses overlapped with published data corrected for the 
unbound fraction of clozapine (3%) (Clozapine Product Insert, 2013).  Subsequently, 
plasma exposures were linked to the plasma–brain structural PK parameters, using 
allometric scaling, that described clozapine and norclozapine transport between plasma 
and brain in the rat to ultimately predict human brain ECF exposure. This population 
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pharmacokinetic approach, based on a transit compartmental approach as opposed to 
explicit assumption of a Pgp role and its associated interspecies scaling, enabled 
translational representation of the system across species to predict human brain ECF 
concentrations. As an atypical antipsychotic drug, clozapine targets D2 receptors as well 
as acts as an agonist or antagonist at several other receptors found in the CNS.  In order 
to get a more complete profile of PK-PD linkage, percentage receptor occupancy of each 
receptor was calculated from 6 to 24 hour after three dosage levels. Our results show that 
the median percentage D2 receptor occupancy was in a range of 42% to 59% 6 hours 
after administration of a daily dose of 200-400 mg. This range is congruent with the 33% 
to 67% range reported by  Nordström et al (Nordström et al., 1995), and agrees with the 
widely recognized understanding of low D2 receptor occupancy of therapeutic doses of 
clozapine relative to those obtained with therapeutic doses of other antipsychotics (first 
and second generation).  In addition to D2, percent 5-HT2a receptor occupancy also 
overlapped with the results of Nordström et al.   
         The proposed PK model thus demonstrated the ability to extrapolate human 
systemic exposure to predict clozapine brain concentrations and associated receptor 
occupancy profiles in humans at clinically relevant doses.  In addition, the model 
simultaneously captured parent and metabolite in the system, which is relevant since 
norclozapine also has activity at multiple receptors (Bishara et al., 2008). However, the 
model can be improved in the precision of the PK parameter estimates by increasing the 
sample size. With this limitation taken into consideration, the model framework reported 
shows promise in predicting clozapine receptor occupancy at multiple receptors in human 
CNS, which can then be probed as a correlate to response and/or toxicity. 
                                                                          40 
 
CHAPTER III: Population Pharmacokinetic Modeling of Sertraline Treatment in 
Alzheimer’s disease Patients: The DIADS-2 Study (Published in The Journal of Clinical 
Pharmacology) (This material is reproduced with permission of John Wiley & Sons, Inc.) 
1. Introduction 
         Alzheimer’s disease (AD) is a neurodegenerative disease associated with a number 
of neuropsychiatric symptoms (NPS). One commonly found NPS is depression, affecting 
as many as 60% of AD patients (Steinberg et al., 2008). The antidepressant sertraline, a 
selective serotonin reuptake inhibitor (SSRI), has been used for the treatment of 
depression in AD patients (Martin et al., 2006). It is the second most potent inhibitor of 
serotonin reuptake (Hiemake et al., 2000).  In a study of 117 randomized controlled trials 
from 1991 to 2007, sertraline was proposed as the best first line treatment for moderate to 
severe depression in adults based on an overall evaluation of benefits, acceptability and 
other factors (Cipriani et al., 2009). Sertraline is orally administered with high plasma 
protein binding affinity (Owen et al., 1997). The average elimination half-life of 
sertraline is approximately 26 hours and the peak plasma concentration (Cmax) is reached 
at 6-8 hours (Warrington et al., 1991). Sertraline is mainly eliminated by hepatic 
metabolism to its major metabolite, N-desmethylsertraline, by multiple cytochrome p450 
enzymes including CYP2B6, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 (Kobayashi et 
al., 1999). This metabolite has 5 -10% of sertraline’s serotonin reuptake inhibitor potency; 
thus its clinical effect on sertraline response is negligible (Sprouse et al., 1996). 
             The pharmacokinetic profile of sertraline has been broadly explored in previous 
clinical studies where patient ages spanned broad ranges (Muijsers et al., 2002; Schneider 
et al., 2003; Axelson et al., 2002). In a pharmacokinetic study of 16 elderly (≥65 years of 
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age) patients treated with 100 mg sertraline once daily for 14  days, plasma sertraline 
clearance was approximately 40% lower compared to similarly studied younger ( 25-32 
years ) patients  (Warrington et al., 1991; Zoloft product information New York: Roeg, 
2001). A comparable result was found in a 21 day study (n=44), with the elimination rate 
constant (0.019 / hr) in elderly individuals 16 to 63% lower than that observed in young 
adults (Ronfeld et al., 1997).  
 In the elderly, sertraline’s effectiveness is comparable to the SSRI fluoxetine as 
well as the tricyclic antidepressants (TCAs) nortriptyline, amitriptyline and imipramine. 
It has lower rates of adverse side effects than the TCAs (Muijsers et al., 2002). Although 
many studies have examined the sertraline pharmacokinetic profile in elderly subjects, 
non-compartmental methods were employed that have limitations in assessing sources of 
inter-individual variability in sertraline concentration. In fact, this is the first population 
pharmacokinetic (PPK) study focusing on AD patients with depression. While this 
analysis was based on data from a null clinical study, it provided an opportunity to 
capture the pharmacokinetic characteristics in elderly individuals of sertraline.  In these 
analyses, we aim to gain insights relating to inter-individual variability in the 
pharmacokinetics of sertraline in AD patients. The objective is to identify covariates that 
contribute to variability in sertraline concentration by performing a PPK analysis of 
sertraline in elderly patients with AD and generating PPK parameters for this population.  
2. Materials and Methods 
2.1 Participants and Study design 
The design of the multicenter Depression in Alzheimer’s Study-2 (DIADS-2) has 
been described in detail elsewhere (Martin et al., 2006; Rosenberg et al., 2010; Weintraub 
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et al., 2010; Drye et al., 2011).  Briefly, DIADS-2 enrolled 131 AD patients with mild-to-
moderate AD.  Patients were randomized in a, 12-week, double-blind, placebo-controlled 
(n=64) antidepressant trial of sertraline (n=67; range: 25-125 mg per day). An initial 
treatment regimen of sertraline 50 mg QD or identical-appearing placebo was prescribed. 
The dosage of sertraline in the active treatment arm was increased to 100 mg QD after 
one week. The daily dose was adjusted depending on the response and tolerability of the 
treatment in the first four weeks post randomization. Single concentration samples of 
sertraline were collected in individual patients at weeks 4 and 12.   The time of last dose 
and exact time of collection were available for each of these samples. 
The study was approved by Institutional Review Boards at all five study sites and 
the coordinating center: Johns Hopkins School of Medicine, Baltimore, MD; University 
of Pennsylvania School of Medicine, Philadelphia, PA; Medical University of South 
Carolina, Charleston, NC; University of Rochester School of Medicine, Rochester, NY; 
University of Southern California Keck School of Medicine, Los Angeles, CA; Johns 
Hopkins Bloomberg School of Public Health. In addition, the PPK analysis was approved 
by the institutional Review Board of Indiana University School of Medicine, Indianapolis, 
IN. 
2.2 Analytical Procedure to Measure Sertraline Concentration  
Plasma sertraline concentration was determined using high-performance liquid 
chromatography (HPLC). The extraction of plasma was done in the mobile phase at a 
60:40 ratio of 0.025 M potassium phosphate buffer, pH 2.5, and acetonitrile with a flow 
rate of 1 mL/min. The separation of plasma occurred in a Knauer nucleosil, C18, 100 
angstrom, 150 mm x 4.6 mm column with a Supelco pelliguard LC-18, 2 cm X 4.6 mm 
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pre-column cartridge. Ninety microliters of n-octylamine was added as a modifier to the 
mobile phase and degassed. The sertraline and D-sertraline assays were linearized by an 
internal standard, 200 ng/mL of clomipramine, in the range of 10 to 600 ng/mL. The 
intra-assay and inter-assay variability in the coefficient of variation (CV) ranged from 
6.6% to 9.4% and ranged from 2.8% to 6.3%, respectively. With 1 mL of plasma, 
recovery for sertraline and metabolite ranged from 87% to 93% with a lower limit of 
quantification (LLOQ) of 10ng/mL. The analysis was carried out using a Turbo Chrom 
data system.          
2.3 Population Pharmacokinetic Model Development 
The population pharmacokinetics of sertraline were analyzed using nonlinear 
mixed effect modeling software, NONMEM, Version VII (GloboMax_LLC, Ellicott City, 
MD, USA) using Wings for NONMEM, Version 7 (Holford,2012). The initial model 
development focused on a base model structure on PK parameter assessment.  One and 
two compartment models with first order absorption and elimination were evaluated 
using subroutine ADVAN2 TRANS2 and ADVAN4 TRANS4, respectively. A likelihood 
based approach (Method 3) was used to handle measurements below the quantitation 
limit (BQL) at 10 ng/mL (Ahn et al., 2008). 
PPK analyses used the first-order conditional estimation (FOCE) LAPLACIAN 
method. Inter-individual variability (IIV) for PK parameters was assumed to be log-
normally distributed and evaluated using an exponential model Pi = PTV x e
ηp
 where Pi is 
the parameter estimate for the ith individual, and PTV is the typical value for the parameter 
at the population level. The variability between ith individual and population parameter 
values was described by p which was identically distributed with a mean of 0 and a 
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variance of ωη
2
 (Feng et al., 2006).  In addition to the IIV, intraindividual variability, 
system noise, experimental error and/or model misspecifications was described by a 
residual error model.  The residual error models evaluated were: additive (
ijijij yy  ˆ ); 
proportional ( )1(ˆ ijijij yy  ); and combined ( ')1(ˆ ijijijij yy   ); where ijy and ijyˆ
represents the jth observed sertraline concentration, and its corresponding model 
predicted concentration with the difference described by 
ij or 'ij . ij  was assumed to be 
normally distributed with a mean of 0 and a variance of 2. The absorption rate constant 
(Ka) was fixed to 0.5 based on the literature values of tmax and an elimination constant 
(Ronfeld et al., 1997).  This was done because the estimation of Ka in this dataset 
resulted in unstable model runs.  
To evaluate the inter-individual variability estimated by the nonlinear mixed 
effects modeling approach, patients’ demographic characteristic (weight, height, age, sex, 
race and study site) were evaluated to see if these explained this variability. These factors 
were assessed independently in a step-wise forward addition approach. Covariates such 
as weight, height, age, sex and race were included to examine potential physiologic 
differences that could contribute to difference in drug elimination rate or distribution 
volume across this population. Given the possibility of differences in adherence to the 
protocol by either subjects or the study site in sample collections, etc, clinical site was 
also tested as a covariate. 
              For continuous covariates, the effects of the covariates on PK parameter 
estimates were tested in the following model structures: 
                   (1) PTV = θ1+ θ2*Cov                                                                                                                  
                   (2) PTV = θ1+ θ2*(Cov - Medcov))                                                                                               
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                   (3) PTV = θ1*(Cov / Medcov)
2
                                                                                                    
                   (4) PTV = θ1*exp[θ2*( Cov / Medcov)]                                                                                       
where PTV  is the typical population estimate of a particular PK parameter, and θ1 and θ2 
are fixed effect estimates for a corresponding covariate, Cov normalized by the median 
value of the covariate, Medcov. Missing data were found in both weight and height 
covariates. A naïve substitution approach (Yang et al) was carried out to simply replace 
the missing value with the median value based on sex.  
                    (5) IF (WT=0 and SEX=1) THEN WT= MedWT,Sex=Male                                                                                                                                                                    
           IF (WT=0 and SEX=2) THEN WT= MedWT,Sex=Female                                                                                          
A common allometric function of scaling the PK parameters to the 0.75 power of body 
weight was also tested after the missing weight values were replaced. 
                    (6) PTV = θ1*(WT / MedWT)
0.75
   
Categorical variables such as sex, race and site were tested in the following model 
structure. Each category was evaluated in a separate fashion. 
                    (7) IF (Cov.EQ.1) THEN PTV = θ1                                                                                              
           Else PTV = θ2 
For example, each ethnic group was divided into a category, African American=1, 
White=4 and Hispanic/Latinos=5. Each ethnic group was examined separately from other 
races.  In addition, groupings of racial categories were affected when the individual race 
effects were not uniquely identifiable. In this case, θ1 and θ2 are the population PK 
parameter estimates for groupings of race that were uniquely identifiable, in this case 
African American and all others.  
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Model evaluation was based on a likelihood ratio test using the objective function 
value (OFV) from NONMEM. The change in the OFV returned by NONMEM is 
approximately equal to -2 x log likelihood.  The difference in -2 x log likelihood between 
two models that are nested follows a χ2 distribution.  Covariates were added to the model 
in a step-wise addition fashion and remained in the final model if the OFV decreased by 
greater than 3.84 (p-value 0.05, df=1). The final model was further examined using 
goodness-of-fit plots generating using R (Version 2.13) based on the conditional 
weighted residuals distribution and the predicted versus observed sertraline 
concentrations at both the population and individual levels. 
3. Results 
3.1 Patient Characteristics  
         A total of 131 participants entered the trial with 67 randomized to sertraline and 64 
to placebo. Only the concentration measurements taken from patients in the active 
treatment arm (n=67) were utilized for this analysis. An average of 1.7 sertraline 
concentration measurements per individual was available, and 5 of the measurements 
were found below the LLOQ.  Seventeen individuals were removed from the analysis.  
Specifically, 16 individuals lacked sertraline concentration information at both weeks 4 
and 12, and one individual had missing dosage information for both occasions.  In the 
remaining 50 individuals, other single observations were removed as follows: 14 
individuals only had a single sertraline concentration measurement from one of the two 
visits (non-measured visit removed).  Of these 14 observations, 11 were missing a 
concentration measurement, 1 was missing a dosage time associated with a concentration 
sample, and 2 were missing dosage amount information associated with that 
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concentration sample. The PPK analysis was conducted using the remaining 85 PK 
observations from 50 individuals.   
As shown in Table 3.1, the median age of the patients was 75 (range: 53-89). 
There were 20 males and 30 females in the analysis broken down as follows: 18% 
African American; 72% White; and 10% Hispanic.  This analysis included 4 patients with 
missing weight information and 9 with missing height information.   The median values 
of weight and height without considering the missing values were 147 lb (range: 107-245) 
and 64 in (range: 57-72), respectively. 
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Table 3.1. Alzheimer’s disease patient demographics  
 N (%) Mean (SD) Median(range) 
Sample size 50   
Number of observations 85   
Gender  
    Male 
    Female 
 
20 (40) 
30(60) 
  
Race  
    Black/African American 
    White 
    Hispanic /Latino   
 
9 (18) 
36 (72) 
5 (10) 
  
Clinical sites  
    A          
B                                                        
C 
D                                                        
E                                                
 
15 (30) 
11 (22) 
6 (12) 
8(16) 
10(20) 
  
Baseline Age (years)   75 (7.76) 76 (53-89) 
Baseline Weight (Ib) 
Without 4 missing values 
 159 (37.08) 147 (107-245) 
 
Baseline Height (In) 
Without 9 missing  values 
 
 64 (4.45) 64 (57-72) 
 
Sertraline dose 
administered (mg) 
 92.47 (18.62) 100 (25-100) 
Sertraline concentrations 
(ng mL-1) 
Without 5  BQL values 
 62.94 (47.62) 49 (9-229) 
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3.2 Population Pharmacokinetic Modeling 
A one-compartment model with first order absorption and elimination and an 
additive residual error model best described the sertraline data. The population parameter 
estimates of CL/F and Vd/F in the base model were 83.1 L/h and 6,620 L, respectively.  
Inter-individual variability (IIV) was estimated only for CL/F  because a significant 
correlation was found between CL/F and Vd/F. Patients at site C has CL/F approximately 
49% lower than that seen in patients other at other clinical sites ( χ2 = 5.576 df=1, 
p<0.05). The final covariate model was implemented using the categorical covariate 
model structure described in the methods section (equation 7). No other significant 
covariate relationships were found for CL/F or Vd/F. The population PK parameter 
estimates and goodness-of- fit plots for the final model are listed in Table 3.2 and Figure 
3.1, respectively.    
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Table 3.2. Population pharmacokinetic parameter estimates of sertraline in the final model  
 
Parameters Population estimate 
(% SE) 
Inter-individual variability 
(% SE) 
CL/Fsite=C, L/h 43.8(34) 59.33% (31.3) 
CL/Fsite=others, L/h 89.1(12.2) 59.33% (31.3) 
Vd/F, L 6470(70.5)  
Ka, 1/h (fixed) 0.5  
Residual variability 19.6 ng/mL (11.6)  
 
CL/Fsite=C ; clearance adjusted for bioavailability from site C; CL/Fsite=others;; clearance adjusted for 
bioavailability from other clinical sites; Vd/F, Volume of distribution adjusted for bioavailability; 
Ka, rate of absorption; SE, standard error 
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A                                                                                    C 
 
B                                                                                           D 
 
Figure 3.1. Goodness-of-fit plots for the final sertraline model. 
 
Plot of population and individual predicted versus observed sertraline concentrations and plot of 
conditional weighted residuals versus population predicted concentrations and time (hours). 
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4. Discussion 
         Nineteen percent of the variance in pharmacokinetic distribution of sertraline in 
these depressed AD patients was accounted for using a 1-compartment model. The 
population mean CL/F and Vd/F were 83.1 L/h and 6,620 L, respectively. As most 
patients in DIADS-2 were elderly (mean age of 75 years; range: 53-89), the mean 
elimination rate constant of 0.013 1/h is consistent with other literature reported values 
(Ronfeld et al., 1997).  Compared to younger patients, the elderly have a longer sertraline 
half-life, but we found no difference between elderly healthy volunteers in the literature 
and these AD patients. 
In our analysis, CL/F estimates for the four patients with sertraline observations 
below the quantification limits were in the top 24% of all CL/F estimates. Indeed, one 
patient with both observations below the quantification limit had a CL/F value 
approximately three times higher than the typical population value. The cause of these 
high CL/F values is not clear. Many possible factors might be considered, such as fasting, 
poor adherence, or genetic variance.   . 
We also examined the effect of sex, race, age, weight, height and site on the 
variability of the PK parameter estimates. Previous publications have suggested that the 
average half-life is 1.5 times longer in women than in men (Ronfeld et al., 1997). We 
expected to detect an effect of gender on sertraline PK parameters; however, inclusion of 
sex as a covariate in our model yielded a statistically non-significant association. Possible 
differences between males and females were likely undetectable because of the small 
study population. In addition, a commonly reported correlation (Mahmood et al., 2007) 
between plasma clearance and body weight was not detected in this analysis. 
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         Unexpectedly, the only covariate examined that affected PK variability was related 
to a single clinical site. Patients at site C had much lower CL/F than other sites. This 
might be explained by the 3 high sertraline concentrations found in 2 patients out of a 
total of 9 observations from site C.  Nineteen percent of the total variance in inter-
individual on CL/F was explained by incorporating the site as a covariate in this analysis. 
The model CL/F estimates we present that exclude patients at the site C are likely more 
generalizable to the typical AD population. In conclusion, clinical site was a significant 
covariate contributing to the CL/F change. The clinical implications for subjects at the 
outlying site would be important if this represented a true bias in subject selection. In this 
case diminished clearance could lead to a greater risk of adverse effects such as dizziness, 
extrapyramidal effects and hyponatremia. Nonetheless, the subjects at this site were 
found not to differ in demographic nor clinical attributes from the other four sites. This, 
as well as the failure to detect differing incidences of side effects, leads to the more likely 
explanation, that there may have been variations in study procedures such as sampling. 
Site variability in trial procedures is critical to the validity of multi-site trials, and 
population pharmacokinetics may prove helpful in this assessment. If drug administration 
and sample collection procedures were found not to be atypical than this may suggest 
meaningful subject differences in the patient sample at the outlying site e.g., drug 
metabolism or body size as we have found previously (Jin et al., 2010). Therefore, the 
dosage regimen and administration should be closely monitored in a multicenter study in 
order to avoid unnecessary exposures or incomplete treatments. 
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CHAPTER IV: Data quality constrains utility of computational modeling of tumor 
burden in non-small cell lung cancer clinical trials  
1. Introduction 
         Cancer drug development would be more effective if new therapeutics could be 
evaluated with readily available technologies, in fewer patients, observed on treatment 
for shorter periods of time.  One set of strategies to achieve these goals has been 
computational modeling of the longitudinal growth of non-small cell lung cancer 
(NSCLC) in populations of patients and in silico simulation of clinical trials. (Claret et 
al., 2012; Houk et al., 2009; Wang et al., 2009; Fridlyand et al., 2011; Moertel et al., 
1976). The ultimate goal of these efforts is to improve the efficiency of cancer drug 
clinical development (Barrett et al., 2007; Bruno et al., 2009; Bruno et al., 2010).  
         In NSCLC, clinical trial simulations have employed a “two-step” joint model 
(Ibrahim et al., 2010) of overall survival in metastatic disease that was based on a 
longitudinal tumor growth model.  These models were developed with data from nearly 
3,400 patients submitted to the FDA. From 4 randomized phase III clinical trials for 
regulatory approval of bevacizumab, docetaxel, erlotinib, and pemetrexed (Wang et al., 
2009)  the longitudinal growth model was derived from the sum of the longest dimension 
measurements of tumors by computed tomography (CT) imaging as recorded in study 
case report forms. Interpolations of the change in tumor size from baseline to 8 weeks of 
treatment (the tumor size ratio or TS) proved an important predictor of overall survival.  
Modeling and simulation with these data could be an efficient means to support decision 
making at the Phase 2 to Phase 3 transition in drug development (Claret et al., 2012).    
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             Another potential benefit of quantitative analysis of NSCLC tumor burden would 
be to redesign phase II trials to randomize fewer patients and have shorter observation 
periods than required for determining progression-free survival (Adjei et al., 2009; Dhani 
et al., 2009; Maitland et al., 2011; Maitland et al., 2011; Mandrekar et al., 2010; Stein et 
al., 2011; Yap et al., 2010).  A simple strategy in NSCLC would be to measure the 
median change in tumor size at 8 weeks for randomly-assigned treatments among the 
study arms (Bruno et al., 2009; Lavin et al., 1981; Karrison et al., 2007).  A more 
complex strategy that might ultimately require fewer resources would be to collect all 
tumor measurements from all patients over time and have the cumulative data from 
patients enrolled early in the trial continuously inform a calculated parameter of drug 
effect.  These strategies have had limited testing and require validation.  For example, in 
studies of colorectal cancer therapy and survival outcomes some have found advantages 
to continuous tumor measurement metrics while others have not (An et al., 2011; Kaiser 
et al., 2013; Claret et al., 2013).  
         The purpose of this study was to assess and refine the published FDA longitudinal 
tumor size model for NSCLC using archived tumor measurement data so that modeling 
and simulation might lead to smaller, quicker early phase trials for testing new treatments 
for NSCLC.  We obtained archived case report forms from three randomized clinical 
trials by the Cancer and Leukemia Group B (CALGB) sponsored by the U.S. National 
Cancer Institute (NCI).  We intended to evaluate the power of smaller clinical trials with 
novel endpoints to detect evidence of anti-cancer drug treatment effects.  Instead, we 
found elements of 3 data sets from multi-center clinical trials that could bias comparisons 
between continuous measurement and categorical strategies for improving treatment 
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evaluations.  These findings are likely to be common to historical and current solid tumor 
trial data sets.  Here we identify variance in measurement and recording of CT imaging 
assessments of tumor burden as a modifiable factor that constrains the successful 
development and validation of novel tumor growth assessment metrics. 
2. Materials and Methods 
2.1 Patients 
         Archived case report forms were available from 857 patients enrolled in 3 NCI-
supported studies conducted by CALGB listed in Table 4.1.  These were front-line trials 
in metastatic NSCLC: CALGB 9730 (Lilenbaum et al., 2005) was a phase III randomized 
trial that compared single-agent paclitaxel with combination carboplatin/paclitaxel, 
CALGB 30203 (Edelman et al., 2008) was a randomized phase II trial that evaluated 
eicosanoid modulation and examined cyclooxygenase-2 expression as a positive 
predictive factor for the inclusion of celecoxib in the standard first-line cytotoxic therapy 
regimens, and CALGB 30303 (Miller et al., 2008) was a phase II randomized study of 
dose-dense docetaxel and cisplatin administered every two weeks with pegfilgrastim and 
darbopoetin-alfa with or without the chemoprotectant BNP7787. The inclusion and 
exclusion criteria of the trials were previously published (Edelman et al., 2008; 
Lilenbaum et al., 2005; Miller et al., 2008). 
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Table 4.1. Three U.S. National Cancer Institute (NCI)-sponsored studies conducted by the 
Cancer and Leukemia Group B CALGB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CALGB study Treatment # of patients 
enrolled 
# of patients 
treated & eligible 
Dates of 
accrual 
 
9730 
 
 
paclitaxel vs. 
paclitaxel/carboplatin 
 
561 
 
561 
 
10/1997 – 
12/2000 
30203 
 
carboplatin/gemcitabine + 
zileuton/celecoxib/both 
140 134 12/2003 – 
9/2004 
30303 
 
docetaxel/cisplatin +/-  
BNP7787 
160 151 8/2004 – 
3/2006 
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2.2 Original Clinical Trial Data Collection 
         Data relevant to original reporting of the clinical trial results were captured on case 
report forms and entered into the CALGB digital databases for each of the clinical trials.  
The coded, patient-level data were stored at the Core Statistical Facility for CALGB 
(Durham, NC, USA). Treatment response assessments were conducted according to the 
study protocols.  The CALGB 9730 trial incorporated standard World Health 
Organization response criteria (Miller et al., 1981) based on imaging studies conducted 
every 2 cycles (6 weeks).  Bi-dimensional measurements of radiographically identified-
lesions were typically hand-written into the same data-field on a standard spreadsheet at 
each evaluation time-point.  Treatment was discontinued: when it became intolerable; 
when new lesions were identified; when the product of two perpendicular diameters of 
any measured lesion increased by at least 25%; or when 6 cycles of therapy were 
completed.  Patients were subsequently followed every 3 months for 2 years.  For 
CALGB studies 30203 and 30303, the Response Evaluation Criteria in Solid Tumors was 
employed, and categorical responses were based on the sum of the longest 
unidimensional measurements of criteria-defined “target lesions” (Therasse et al., 2000).  
Thoracic CT imaging evaluations were conducted in all patients pre-treatment, and at 6 
and 12 weeks after treatment.  Patients were removed from the studies for unacceptable 
toxicity or progression of disease.  Patients who completed all study therapy were 
followed at minimum every 12 weeks thereafter.   
         For studies 30203 and 30303, tumor measurements were recorded on the “CALGB 
Solid Tumor Evaluation Form” – C-660.  The form designates separate rows for each 
target lesion and columns for each evaluation time-point. The longest unidimensional 
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measurement was entered for each designated target lesion at baseline in a separate row.  
Non-target lesions were identified as present in a separate section of the form. During the 
studies the original case report forms were transmitted by the sites to the CALGB 
Statistical Facility where the forms were reviewed and verified by the data management 
team and the RECIST categorical evaluations were entered into digital databases. The 
sum of the longest dimensions of target lesions and the target lesion measurements were 
not captured in the study database. After publication of study results, the case report 
forms and associated source document CT reports were stored off-site in an archive 
facility. 
2.3 Tumor Measurement Collection   
         To obtain the original target lesion measurements, the archived paper case report 
forms were obtained from storage, scanned, and saved as portable document format (pdf) 
files.  Tumor measurements from the pdf files for CALGB 30203 and 30303 were 
manually extracted by a research assistant and entered into a tracking file and into the 
study databases simultaneously.  The transcriptions were independently reviewed by one 
of the study authors (SK and CL) and inconsistencies were manually corrected.  
Additionally, individual patient tumor growth plots were inspected for atypical growth 
and response patterns.  All aberrant plots were cross-verified with the original case report 
form pdf and any additional data entry errors captured by this review were corrected 
before modeling analyses were performed.  This process (Figure 4.1) resulted in 103 
patients with evaluable data from CALGB 30203 and 124 from CALGB 30303.  A 
sample of case report forms from CALGB 9730 (Figure 4. 2), consistently revealed 
insufficient documentation of quantitative measurements of tumors to be useful for this 
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modeling exercise, and therefore all patients from this trial were excluded from our 
planned evaluation. 
 
 
Figure 4.1. Selection of patients contributing images from CALGB 30203 and 30303. 
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Figure 4.2. An example of a case report form from CALGB 9730 trial. 
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2.4 Tumor Size Modeling 
         Longitudinal tumor size trajectories (sum of longest tumor diameter) were analyzed 
with nonlinear mixed effect modeling software, NONMEM, Version VII 
(GloboMax_LLC, Ellicott City, MD, USA) using Wings for NONMEM, Version 7 
(Holford, 2012) and the published model structure (Wang et al., 2009).  This model 
employed a combination of a linear growth function and an exponential shrinkage 
function to describe the tumor change respect to baseline size (Eq.1). 
tPReBASEtTS i
tSR
ii
i  )(  
Where )(tTSi is the tumor size at time t for the 
thi individual, iBase is the baseline tumor 
size, )(tSRi is the exponent tumor shrinkage rate constant, and )(tPRi is the linear tumor 
growth rate constant. The exponential shrinkage function constrains the tumor size to be 
greater than zero (to avoid negative tumor sizes being predicted) and reflects the drug 
effect on tumor (whether or not there is actual tumor shrinkage).  Tumor size changes 
were modeled using the first-order conditional estimation (FOCE) and stochastic 
approximation expectation maximization (SAEM) method with interaction. Between 
subject variability was assumed to be log-normally distributed and  evaluated on baseline 
tumor size, tumor shrinkage rate and tumor progression rate using an exponential model 
Pi = PTV x e
ηp
 where Pi is the parameter estimate for the 
thi individual and PTV is the 
typical value for the parameter at the population level.  The variability between thi  
individual and population parameter values was described by p which was identically 
distributed with a mean of 0 and a variance of ωη
2
 (Feng et al., 2006).  Residual 
variability was also estimated using a proportional residual error model ( )1(ˆ ijijij yy  ) 
where 
ijy and ijyˆ represents the 
thj  observed tumor trajectory, and its corresponding 
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model predicted tumor size.  The difference between observed and predicted values was 
described by 
ij  which was assumed to be normally distributed with a mean of 0 and a 
variance of 2.  
         A likelihood ratio test was applied based on the change in the objective function 
value (OFV) in NONMEM to evaluate the random effect on parameters. This change in 
OFV is approximately equal to -2 x log likelihood.  The difference in -2 x log likelihood 
between two models that are nested follows a χ2 distribution.  An alpha level for 
significance of 0.05 was set a priori (3.84 OFV for 1 degree of freedom).  The final 
model was further examined using goodness-of-fit plots generating using R (Version 2.13) 
based on the conditional weighted residuals distribution and the predicted versus 
observed tumor size measurements at both the population and individual levels. The 
tumor size model was developed to evaluate data from both treatment arms individually 
as well as simultaneously on the combined dataset. 
2.5 Modeling Matched Cases from ECOG 4599 and CALGB 30203 
         The CALGB trial based parameter estimates for the linear growth rate and the 
treatment-related shrinkage rate differed from those originally published from the large 
FDA sample. To determine whether the deviation of the parameter estimates were 
specific to the CALGB data collection we extracted longitudinal tumor measurement data 
from a clinical trial conducted by the Eastern Cooperative Oncology Group (ECOG), trial 
4599.  That study compared front-line therapy with carboplatin and paclitaxel with or 
without the addition of bevacizumab (Sandler et al., 2006). The ECOG4599 data 
constituted more than one fourth the total sample used to generate the FDA model.  One 
hundred three individual cases were selected from the carboplatin, paclitaxel, and placebo 
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arm of ECOG 4599 by matching to the CALGB 30203 sample on patient visit time, 
number of lesions, and sum of the longest diameter of the target lesions at baseline.   
2.6 Calculation of time to tumor growth 
         In addition to change in tumor size at 8 weeks an alternative metric of treatment 
effects on serial tumor measurements, time to tumor growth (TTG) was evaluated (Claret 
et al., 2013) (Figure 4.3).  TTG is expressed in time units (week) and depends on all the 
parameters of the empirical tumor model including baseline (Base, cm), tumor shrinkage 
rate constant (SR, 1/week) and tumor progression rate constant (PR, cm/week) (Eq 2).  
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Figure 4.3. A graphical representation of tumor matrices.    
TTG: time-to-tumor growth estimated using the FDA model; PTR: percentage tumor reduction 
from baseline.  
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2.7 Survival Analysis 
             In order to determine the relationship between tumor size change and overall 
survival, the tumor size model was used to predict tumor size change at early time points 
(4, 6 and 8 weeks).  In addition to the predicted tumor size changes at 4, 6 and 8 weeks, 
time to tumor growth and other clinical risk factors (Table 4.2) were tested in Cox model 
for overall survival using pre-selection with a stepwise significance at 0.05.  For the 
purpose of evaluating the prediction of time to death using measures of tumor dynamics, 
a parametric survival was adapted to estimate this relationship.  Parametric survival 
functions including: exponential; Weibull; and log normal were tested, and the final 
survival distribution selected based on likelihood ratio test and Akaike information 
criterion. 
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Table 4.2. Demographic and clinical characteristics of patients in CALGB 30203 and 30303 
trial.  
Chemo: Chemotherapy; RT: Radiation. 
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2.8 Script to “Clean CRF Data” to Match RECIST 1.1 Consistently 
         When considered a conservative evaluation of longest diameter of tumor size, 
RECIST criteria 1.1 has been proposed to apply for trajectory selection. The tumor 
dynamic data was further manipulated by a script based program implemented using R 
(version 2.13) to extract and calculate the sum of longest diameter of the tumor size at 
each measurement using RECIST 1.1 criteria.  The majority of tumors were measured by 
computed tomography scan (93.3%) and the rest of 6.62% were measured in different 
methods. Besides removing lesions with missing information and deleting individuals 
with baseline measurements only, the script based extraction was further applied to 
comprise the following steps: 1) exclude the lesions with inconsistent follow-up, 2) select 
up to a total of five lesions with a maximum of two lesions per organ and exclude lymph 
nodes if the maximum number of target lesions are exceeded.  
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R script code 
###### import data ########### 
library(MIfuns) 
library(lattice) 
library(reshape) 
 d<-
read.csv(file="C:/Claire/NSCLC1/NSCLC30303TEST2.csv",skip=0,header=TRUE,sep=
",",as.is=TRUE) 
names(d) <- 
c("ID","OID","VISIT","TREATMENT","LESION","LOCATION","SIZE","OLOCATIO
N") 
d$SIZE <- as.numeric(as.character(d$SIZE)) 
origi.dat <- d 
write.table(d,file="C:/Claire/NSCLC1/30303TEST1.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
######## calculate sum of baseline tumor sizes ######### 
d1 <- d[d$VISIT==0,] 
reapply <- function(x,INDEX,FUN,...){ 
           y <- tapply(x,INDEX) 
           z <- tapply(x,INDEX,FUN,...) 
           z[y] 
} 
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d1 <- transform(d1,basesum=reapply(SIZE,INDEX=ID,FUN=sum)) 
d1 <- d1[,c("ID","basesum")] 
d2 <-d1[!duplicated(d1$ID),] 
d3 <- merge(d,d2,by.x="ID",by.y="ID",all.x=T) 
write.table(d,file="C:/Claire/NSCLC1/30303TEST2.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
######## remove lesion and size which are missing ######## 
d <- d3 
d <- d[!is.na(d$LESION) & !is.na(d$SIZE),]   
head(d) 
write.table(d,file="C:/Claire/NSCLC1/30303TEST3.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
###### determine which lesions are present for each individual at every visit ###### 
####how many follow up+baseline in each patient  
ni <- length(id <- unique(d$ID)) 
keep.lesion <- NULL 
temp <- NULL 
for (i in 1:ni){ 
    visit <- unique(d$VISIT[d$ID==id[i]])  
    nvisit <- length(visit) 
    s.lesion <- d$LESION[d$ID==id[i]] 
    u.lesion <- unique(s.lesion)  
    n.sl <- length(s.lesion) 
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    n.ul <- length(u.lesion) 
    l <- data.frame(u.lesion,rep(0,n.ul)) 
    names(l) <- c("lesion","times") 
 
    for (j in 1:n.ul) { 
        for (k in 1:n.sl) { 
           if (u.lesion[j]==s.lesion[k]) 
           l$times[j] <- l$times[j]+1     
        } 
    } 
    l <- l[l$times==nvisit,] 
    temp <- data.frame(rep(id[i],length(l$lesion)),l$lesion,rep(nvisit,length(l$lesion)) 
    keep.lesion <- rbind.data.frame(keep.lesion,temp) 
}  
names(keep.lesion) <- c("ID","LESION","NVISIT") 
write.table(keep.lesion,file="C:/Claire/NSCLC1/30303TEST4.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
####### delete IDs with baseline visit only #######  
dd <- keep.lesion  
dd <- dd[dd$NVISIT >= 2,] 
###### calculate number of lesions that appear at all of the visits ####### 
ni <- length(dd$ID) 
dd$flag <- rep(0,ni) 
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n <- ni-1 
for (i in 1:n) { 
    if (dd$ID[i]==dd$ID[i+1]) 
           dd$flag[i] <- 1 
    else 
       dd$flag[i]<- 0 
}   
dd <- transform( dd, NLESION=reapply(flag,INDEX=ID,FUN=sum)+1) 
dd$flag <- NULL 
keep.lesion <- dd 
######## extract data with only the lesions that appear at all of the visits 
###############  
a <- merge(d,keep.lesion,by=c("ID","LESION"),all.y=T) 
a <- a[order(a$ID,a$VISIT,a$LESION),] 
a <- 
a[,c("ID","VISIT","LESION","SIZE","basesum","NLESION","TREATMENT","LOCA
TION","NVISIT")] 
all.lesions <- a 
write.table(all.lesions,file="C:/Claire/NSCLC1/30303TEST5.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
### add flag for lesions which are labled as "LYMPH NODE" ###### 
flag <- rep(0,length(a$ID)) 
for (i in grep("LYMPH NODE",a$LOCATION)){ 
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    flag[i] <- 1 
} 
a$LYM <- flag 
lym <- a[a$LYM==1,c("ID","LESION","LYM")] 
lym <- unique(lym) 
write.table(lym,file="C:/Claire/NSCLC1/30303TEST6.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
a$LYM <- NULL 
a <- merge(a,lym,by=c("ID","LESION"),all.x=T) 
a <- a[order(a$ID,a$VISIT,a$LESION),] 
a$LYM[is.na(a$LYM)] <- 0 
 
write.table(a,file="C:/Claire/NSCLC1/30303TEST7.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
######### calculate sum of lesions size at each visit for IDs with <= 3 lesions present at 
each visit ############  
a1 <- a[a$NLESION <=3,] 
aa1 <- 
aggregate(x=list(visitsum=a1$SIZE),by=list(ID=a1$ID,VISIT=a1$VISIT),FUN=sum) 
aa1 <- aa1[order(aa1$ID,aa1$VISIT),] 
a1 <- merge(a1,aa1,by=c("ID","VISIT"),all.x=T) 
a1 <- a1[order(a1$ID,a1$VISIT,a1$LYM,-a1$SIZE),] 
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write.table(a1,file="C:/Claire/NSCLC1/30303TEST8.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
##### IDs lesion # >3 #######  
a2 <- a[a$NLESION >3,] 
a2 <- a2[order(a2$ID,a2$VISIT,a2$LYM,-a2$SIZE),] 
write.table(a2,file="C:/Claire/NSCLC1/30303TEST9.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
##### identify three lesion numbers with biggest size at baseline and exclude "lymph 
node" for #lesion >=4 #######  
d <- a2[a2$VISIT==0,c("ID","LESION")] 
 d1 <- NULL 
 temp <- NULL 
 ni <- length(id<-unique(d$ID)) 
for (i in 1:ni){ 
    lesion <- unique(d$LESION[d$ID==id[i]])  
    nlesion <- length(lesion) 
    temp <- data.frame(rep(id[i],3),lesion[1:3]) 
    d1 <- rbind.data.frame(d1,temp) 
} 
names(d1) <- c("ID","LESION") 
d1 <- d1[order(d1$ID,d1$LESION),] 
v <- d1 
########### calculated sum of three largest lesion sizes at each visit ############  
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v1 <- merge(v,a2,by=c("ID","LESION"),all.x=T) 
vv1 <- 
aggregate(x=list(visitsum=v1$SIZE),by=list(ID=v1$ID,VISIT=v1$VISIT),FUN=sum) 
v1 <- merge(v1,vv1,by=c("ID","VISIT"),all.x=T) 
a2 <- v1 
a2 <- a2[order(a2$ID,a2$VISIT,a2$LYM,-a2$SIZE),] 
a2$NLESION <- 3 
######### combine two subset together #########  
a <- rbind.data.frame(a1,a2) 
###a$TREAT <- ifelse(a$TREATMENT=="PLACEBO",0,1)#### 
a <- a[,c("ID","VISIT","LESION","SIZE","visitsum","basesum","NLESION" 
,"LYM","TREATMENT","NVISIT")] 
names(a) <- c("ID","VISIT","LESION","SIZE","VSUM","BSUM","NLESION" 
,"LYM","TREATMENT","NVISIT") 
a <- a[order(a$ID,a$VISIT,a$LYM,-a$SIZE),] 
######## export dataset with all ids ###########  
write.table(a,file="C:/Claire/NSCLC1/NSCLC30303FINAL.csv", 
sep=",",append=F,quote=F,col.names=T,row.names=F,na=".") 
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2.9 Blinded Re-Evaluation of Imaging Data 
         To identify sources of variance between patient outcomes and the modeled 
change in tumor size over time, we obtained the original sets of images from patients 
enrolled at the University of Chicago in studies 30203 and 30303.  One radiologist, 
blinded to the original case report forms and radiology reports (co-author AO) reviewed 
all of the baseline images and identified and measured all target lesions.  Unblinded to the 
lesions, but still blinded to the original measurements, the radiologist performed serial 
measurements on the identified target lesions on the University of Chicago patients. 
3.Results 
3.1 Data Quality Control 
         We discovered that 9730 study case report forms (CRFs) frequently included no 
change (nc) or not available (na) rather than tumor size measurements on subsequent CT 
scans as in Figure 4.2.  Consequently the entire trial data set had too much missing data 
to be useful for validating the longitudinal tumor growth model and data from all 561 
subjects was excluded.   
         For the CALGB trials, we subjected the patients’ data to the same standard for 
inclusion as in the FDA model (at least a baseline measurement and measurements 
recorded at some subsequent time-point).  Figure 4.1 describes the attrition for 140 
original cases in the CALGB 30203 trial and 160 in CALGB 30303. This resulted in a 
total of 227 patients available for the analyses.  
3.2 Longitudinal Modeling of Tumor Size 
         Parameter estimates for sum of longest tumor dimensions at baseline (M_BASE), 
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the treatment-effect/shrinkage rate (M_SR), and the linear tumor growth rate (M_PR) 
were determined and compared to the results of similar study arms from the original 
study as shown in Table 4.3. The individual predictions vs. observations of sum of the 
longest diameter were compared in each individual between FOCE and SAEM methods. 
The final parameters were estimated using SAEM based on individual fitting. 
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Table 4.3. Tumor model parameter estimates and precision standard error (SE) of baseline 
(M_BASE), shrinkage rate (M_SR) and progression rate (M_PR) for FDA registration 
trials and CALGB 30203 and 30303 trial. 
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              Variance in parameter estimates increased as sample size was reduced from 
typical phase III to typical phase II size study arms.  With a combination of both 30203 
and 30303 trials, the model estimates of baseline tumor size, shrinkage rate and 
progression rate were 8.44cm, 0.027 1/week and 0.066 cm/week, respectively.  For 
example a patient with an average baseline tumor size at 8.1cm will after 1 month, have 
the typical tumor burden decrease to 8.44e^(-0.027 x 4)+ 0.066 4=7.84cm. This 7.1% 
decrease reflects the drug effect on tumor size.  Compared to the average parameter 
estimates from five treatment arms of FDA data, the CALGB results underestimated 
M_BASE, M_SR, M_PR in 3%, 48% and 57%, respectively.                                                                  
         These differences in tumor size and growth metrics between the smaller CALGB 
dataset and the FDA dataset were associated with tumor size at 8 weeks no longer being a 
statistically significant predictor of survival in NSCLC (Table 4.4). This inconsistency in 
the prediction of survival by tumor size with data collected by an experienced 
cooperative clinical trials group undermined plans to replace RECIST with continuous 
measures of tumor burden in smaller, prospective, randomized phase II trials. We 
conducted additional studies to identify factors in acquisition of these data that might 
have led to this unexpected finding. 
         Furthermore, no significant changes in the tumor parameter estimates were 
observed when applying additional script-based filtration by adding the restriction of 
number of the lesions, consistence of follow-up and number of lymph nodes. 
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Table 4.4. Comparison of tumor parameter estimates between CALGB30203 trial and a 
subset of E4599 trial which matched to CALGB30203 tumor information. 
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3.3 Evaluation of deviations in parameter estimates and survival prediction 
         First we hypothesized that these lower estimates might reflect lower quality of data 
from small cooperative group trials compared to perhaps more meticulously accurate data 
submitted to the FDA for review. We therefore matched 103 patients from the ECOG 
4599 study carboplatin/paclitaxel arm, part of the dataset used to generate the FDA model, 
with the 103 CALGB 30203 cases (who received carboplatin/gemcitabine).  For this 
subset of matched cases in ECOG 4599 the mean baseline tumor size was larger, but the 
parameter estimates for M_SR and M_PR were now more similar to CALGB 30203 than 
to the results for the entire 444 subject carboplatin/paclitaxel arm of  ECOG 4599 (Table 
4.4). This implied that the deviation of parameter estimates between the CALGB data and 
the similar, but larger, treatment arms in the FDA dataset were unlikely to be due to 
significant differences in data quality between trials conducted by different groups, and 
instead reflected effects of decreasing the size of the analyzed subject pool. 
         Some recent studies suggested that TTG might be more robust than tumor size at 
early fixed time-points for colorectal cancer (Claret et al., 2013) and NSCLC (Claret et 
al., 2014).  We therefore tested whether TTG might be a significant predictor of survival 
in the CALGB 30203 and the matched E4599 smaller dataset. In the Cox proportional 
hazard model for CALGB 30203 patients, the baseline tumor size (centered at 8.5cm) (P< 
0.001) and TTG (P<0.001) were significant predictors of time to death when incorporated 
as independent factors.  The p-value of each coefficient was no longer significant when 
both factors were tested in the survival model simultaneously.  The TTG and baseline 
tumor size were correlated (r = 0.75) ( P<0.001).  Therefore, the final survival model 
included the baseline tumor size and ECOG performance status (0/1/2) (Eq 3). 
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log(T)=0 + 1  (baseline-8.5) +2 ECOG + 
where T is time to tumor death (day) in a log normal distribution, 0 is the intercept when 
no covariate was added, 1 and  2  are the coefficients for baseline-8.5 and ECOG, 
respectively, and  represents the residual error. In the matched subset of E4599 patients, 
TTG remained a statistically significant predictor in this model.  However, when tested in 
the remaining 232 subjects of the carboplatin/paclitaxel arm, TTG was no longer a 
significant predictor of survival.  We concluded that this loss of tumor size as a 
significant predictor of survival in smaller datasets was not an effect of the specific 
parameter of continuous measurement of tumor burden.   
         A difficult-to-test hypothesis is that the model accurately reflects that the CALGB 
30203 and E4599 subsets of patients are genuinely different from the larger population of 
patients on which the FDA model was based.  Our experience with the multi-step process 
of CT-imaging measurement and transmission of measurements into clinical trial 
databases offers an alternative hypothesis: the routine variance in tumor burden 
measurements introduced by our current RECIST-oriented clinical trial methods 
contributes significantly to this loss of power because of the inherent variance introduced 
with this approach.  This variance further confounds computational models of continuous 
tumor growth reducing their ability to accurately predict survival in patient populations 
typical of phase 2 trials. 
         We therefore explored specific modifiable factors in the collection and reporting of 
tumor measurements might contribute to the altered shrinkage rate and growth rate 
parameter estimates in the longitudinal growth model when the size of the population was 
decreased. To evaluate the reproducibility of the tumor measurements on the case report 
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forms, an independent radiologist in blinded fashion re-determined and measured the 
baseline target lesions from the original CT images collected from 15 patients enrolled in 
CALGB 30203 and 30303 at one institution (Figure 4.4A). For 4 of the 15 patients, at 
least one additional target lesion was identified.  Once unblinded to the determination of 
target lesions, the radiologist performed blinded serial measurements of the designated 
lesions (Figure 4.4B). Although displayed for consistency, 3 of the 15 subjects did not 
have an on-treatment assessment and therefore were not included in subsequent modeling 
analyses.  For the 12 cases with serial measurements, 4 (subjects 7, 8, 9, 12) had 
trajectories of the measured sums of longest dimensions that were nearly superimposable 
between the case report forms (CRF) and the blinded evaluator re-assessment. Four 
(subjects 1, 3, 4, and 5) had obvious divergence between the CRF and blinded 
evaluations in terms of the magnitude of change in tumor burden and time-points at 
which these changes are registered. The remaining 4 had differences of unclear 
significance (2, 6, 10, 11).  
3.5 Estimated impact of continuous measurement variance on modeled endpoints 
         RECIST was developed to be robust to inter-rater variance in measurements by 
setting categories for tumor size changes (Progressive Disease, Partial Response, and 
Complete Response) based on thresholds for magnitudes of change that would be 
unlikely to be due to the greatest degree of inter-rater variance (Therasse et al., 2000).  A 
patient’s category of response would then likely only be due to a significant effect of 
treatment (Moertel et al., 1976; Miller et al., 1981). It is therefore not surprising that in 
settings where inter-rater variance is not actively controlled, assessments of continuous 
                                                                          84 
 
measurements of tumor growth will not improve upon our current RECIST-based 
categorical and time-to-event strategies              
         We hypothesized that this inter-rater variance in tumor burden assessments would 
have a significant effect on a continuous-measurement-based strategy such as TTG with 
less effect on a RECIST-based time to event endpoint such as progression-free survival 
(PFS). For the 12 subjects with serial CRF and blinded radiologist measurements (Table 
4.5), we identified an average 25% delay in TTG calculated from the re-evaluated scans 
compared with the CRF data, but no differences in PFS assessments.  Despite differences 
in target lesion assessment and measurement, subjects met criteria for progressive disease 
at the same imaging session in both datasets. 
 
 
 
 
 
 
 
 
 
 
                                                                          85 
 
A) 
B) 
 
 
Figure 4.4. Comparisons of identified target lesion measurements from original case report 
forms and by blinded radiologist reviewer.   
A) Target lesion measurements from CALGB 30203 and 30303.  X-axis; Yellow circles; CRFs 
(case report forms), Blue circles; BE (Blinded re-evaluation of imaging data by radiologist from 
the University of Chicago).  Y-axis; Each circle depicts one lesion at baseline (BL) visit in 
centimeters (cm).  Gray line between yellow and blue circle connects the same lesion. B) Sum of 
the longest dimensions (cm) at each assessment time point for subjects in A over the course of the 
trial. 
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Table 4.5. Comparisons of PFS and calculated TTG from the target lesion measurements by 
blinded radiologist evaluation (BE) and case report form (CRF) data 
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4. Discussion 
         This examination of a NSCLC longitudinal tumor growth model and endpoints in 
published CALGB studies revealed current limitations to employing continuous 
measurements of tumor burden in phase II clinical trials. Modeling of typical phase III 
clinical trial-size samples has reproducibly demonstrated tumor burden metrics as 
predictors of survival (Claret et al., 2012; Stein et al., 2011; Claret et al., 2013; Stein et al., 
2012). Contrary to our expectations, we showed that decreasing the sample size to that of 
a typical phase II trial results in complete loss of the predictive power of these tumor 
metrics. Even though TS at 8 weeks is no longer a statistically significant predictor of 
survival in NSCLC with a typical phase II sample size, the direction of this predictor to 
survival remains the same as observed in the large phase III trials. As Bonate illustrated 
in a simulation study based on the FDA model structure, the parameter bias did not 
translate to prediction bias in tumor size as the measurement error with the expected 
bounds for tumor size assessment (Bonate et al., 2013). This suggests that we cannot rule 
out the clinical utility of TS at early time points in phase II survival prediction because of 
the low predictive power in a small size trial. In fact, other sources of variance such as 
phase II survival data in contributing to the model predictability may also need to be 
evaluated. Closer scrutiny of the original images and the recorded data revealed variance 
in the process by which tumor burden is assessed and recorded to meet RECIST 
standards.  This variance has no apparent effect on RECIST categories or time-to-event 
endpoints, but does affect tumor burden metrics.  
         There is no superior alternative approach to RECIST for the standardized 
assessment of anatomical tumor burden and its change over time (Eisenhauer et al., 2009; 
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Fojo et al., 2012).   This categorical system applied to quantitative assessments of tumor 
burden provides low inter-rater variance (progressive disease will be determined with 
high uniformity across sites in a multi-center trial and among trials) at the expense of 
efficiency (requires more patients to be observed over long periods of time).  Our 
findings are consistent with investigators collecting and curating the quantitative tumor 
burden data with sufficient precision to support use of RECIST but not to support more 
computationally intensive methods of evaluating effects of treatments in small clinical 
trials.  It is no surprise that many investigators have found no significant advantages to 
use of quantitative methods (such as tumor size ratio) over more qualitative time-to-event 
strategies (such as progression-free-survival) for predicting impact on overall survival 
(Fridlyand et al., 2011; An et al., 2011; Kaiser et al., 2013).   
         This study had a limited data sample for analysis, but it required significant effort to 
obtain these data.  The qualitative documentation of tumor response data in earlier trials 
was not suitable for further quantitative analysis.  For the more recent trials, the primary 
databases maintained the RECIST-based categories in data fields, but obtaining the 
quantitative tumor measurements required manual retrieval and processing of archived 
paper forms.  The small cohort of patients for whom images were available and reviewed 
might have been a biased sample, but this site had been a major contributor to enrollment 
across thoracic oncology trials in CALGB with the stringent audit and quality control 
processes applied for member sites.  The data are therefore likely representative of the 
overall quality of data in the larger clinical trials.  Furthermore, an independent trial, 
conducted by a completely different set of institutions (ECOG) yielded similar results. 
We cannot exclude the possibility that this particular subset of patients matched between 
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the CALGB and ECOG datasets represents a unique group of NSCLC patients whose 
tumor growth patterns are distinct from the typical patient population.  Therefore our 
findings will require confirmation in other datasets. 
         The study demonstrates a potential major flaw in assumptions on the use of 
quantitative measures of tumor burden and computational analysis.  The process of 
measuring, transmitting, analyzing, and interpreting CT imaging-based measures of 
tumor contributes significant, but potentially modifiable variance.  Centralized collection 
and measurement of CT images with semi-automated and digitally enhanced procedures 
should significantly reduce this variance.  Advances in computing and digital data 
management in the past several years have reduced costs and make paperless systems 
with fewer opportunities for manual error possible.  Our findings suggest that 
establishing methods with less inter-rater variance should be a worthwhile investment in 
the future of cancer therapeutics assessment. 
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CHAPTER V: Clinical Trial Simulation to Evaluate Study Design: Capturing 
Abiraterone and Nilotinib Exposures  
1. Introduction 
         In the past twenty years, oral anticancer drug therapy has become more prevalent 
(Singh et al., 2004). Unlike intravenous drug administration, orally administered agents 
undergo absorption from the gastrointestinal lumen through the intestinal epithelium into 
the portal vein and then into the systemic circulation. The fraction of an orally 
administered drug dose that reaches the systemic circulation is the drug’s oral 
bioavailability and significant differences or changes in bioavailability will lead to a 
significant variation in drug exposure (Martinez et al., 2002) and thus modified 
therapeutic and or toxic effects.   
One of most well-known factors contributing to variability in oral bioavailability 
is food intake (Singh et al., 2004; Winstanley et al., 1989; Gu et al., 2007). The effect of 
food on oral bioavailability has the potential to cause a clinically significant impact by 
causing variable systemic drug exposures that can lead to drug toxicity or therapeutic 
failure (Koch et al., 2009; Kang et al., 2010).  Furthermore, the alternation of 
pharmacokinetic profile of several standard and investigational anticancer drugs such as 
busulfan, topotecan and fluorouracil caused by food-drug interactions have been 
previously reported (Singh et al., 2004). Quantifying the effect of food on drug exposure 
is important when designing a clinical trial for oral anti-cancer drugs.  In addition to food 
related variability, variability in drug pharmacokinetic parameters between individuals as 
well as between occasions within an individual also contributes to variability in drug 
exposure. In order to assess the contribution of different magnitudes of between-
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individual and between-occasion variability on drug exposure, this study used a 
population PK modeling approach and  Monte Carlo methods to simulate a virtual 
clinical trial of patients who took drug in both the fasted and fed states. 
               Such a clinical trial simulation framework provides insight as to whether a 
particular study design, with a random sampling schema to reflect a typical clinical 
practice setting, permits the retrieval of pharmacokinetic (PK) parameters and their 
variability under different prandial conditions.  In addition, simulation of a clinical trial 
can assess how patient specific covariates, between-individual, and between-occasion 
variability affect the ability to accurately capture individual level exposures. The aim of 
this study was to evaluate whether a pre-defined oncology trial with a sparse drug 
concentration sampling schedule can adequately capture individual level drug exposures, 
random variability and the food effects of (1) abiraterone (92% decrease in  oral 
clearance), and (2) nilotinib, (18% decrease in oral clearance). To achieve these 
objectives, a virtual cancer study population was simulated with assigned 
pharmacokinetic characteristics, food intake and between-individual as well as between-
occasion variability. A population pharmacokinetic (Pop PK) approach was utilized to 
retrieve the Pop PK parameters under these conditions and examine whether or not these 
parameters could be adequately retrieved on estimation at both the individual and 
population level.  
2. Materials and Methods 
2.1 Simulation of Patient Pharmacokinetic Characteristics 
Hypothetical patients were created with fasting state Pop PK characteristics 
mimicking those found in oncology patients. (See Table 5.1 for abiraterone (Ryan et al., 
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2010) and Table 5.2 for nilotinib (ZYTIGA, Tanaka et al., 2010) patient characteristics. 
The Pop PK parameters were assumed to be log- normally distributed and the parameter 
values for simulation were obtained or calculated based on literature values from a non-
compartmental analyses (Ryan et al., 2010; ZYTIGA, Tanaka et al., 2010). A one 
compartment model with first order absorption and elimination was assumed as the 
model structure. Between-individual variability of oral clearance (CL/F) and volume of 
distribution (Vd/F) were based on the mean and standard deviation of pharmacokinetic 
parameters from published studies. Abiraterone between-individual variability values for 
oral clearance and volume of distribution were 174% and 73%, respectively, in the fasted 
state and 42.2% and 36%, respectively, in the fed state [7]. The between-individual 
variability of the absorption rate constant was assumed to be 20% and a proportional 
residual error with 30% CV was assumed based on literature values for abiraterone (Ryan 
et al., 2010). For nilotinib, the between-individual variability of oral clearance and 
volume of distribution values were set to 55% and 37% CV, respectively, for both fed 
and fasting states (Tanaka et al., 2010). A between-individual variability for the nilotinib 
absorption rate constant of 20% and a proportional residual error with 10% CV based on 
the lower limit of quantification of the nilotinib concentration assay were assumed 
(Tanaka et al., 2010).   
Values of the Pop PK parameters for each hypothetical patient were randomly 
chosen from their respective distributions with a correlation of 0.6 applied between 
clearance and volume.  
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Table 5.1.  Population pharmacokinetic parameters for abiraterone patients  
Abiraterone 
Parameter Fasting status 
Mean (SD) 
Fed status 
Mean (SD) 
Apparent Clearance / bioavailability [CL/F] 
(L/h) 
2650 (4617) 231 (97.7) 
Apparent Volume of distribution / 
bioavailability [Vd/F] (L)  
25494 (18670) 4069 (1462) 
Absorption rate (1/h) 1.65 (0.33) 1.65 (0.33) 
F = oral bioavailability 
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Table 5.2.  Population pharmacokinetic parameters for nilotinib patients 
Nilotinib 
Parameter Fasting status 
Mean (SD) 
Fed status 
Mean (SD) 
Apparent Clearance / bioavailability 
[CL/F](L/h) 
33 (18) 27(15) 
Apparent Volume of distribution / 
bioavailability  [Vd/F] (L) 
720 (267) 604(181) 
Absorption rate (1/h) 0.74 (0.15) 0.74 (0.15) 
F = oral bioavailability 
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2.2 Food Effects  
For both abiraterone and nilotinib, it was assumed that 50% of doses were taken 
with food and that the values of the oral clearance and volume of distribution depended 
upon whether a particular dose was taken with food or without food.  
To mimic the actual drug administration protocol for food intake, we considered a 
different food effect in the abiraterone versus nilotinib trials. This was done to test 
whether the model would be able to capture two extreme food effects, the between-
individual and between-occasion variability, and the individual level exposure. For 
abiraterone, patients in the fed prandial state were assumed to have had a high fat meal 
given the availability of Pop PK parameter values in the reference for simulation from 
this state; therefore, the oral clearance and volume of distribution were reduced by 92% 
and 85%, respectively, if the dose was taken with food (Ryan et al.,2010). In contrast to 
the abiraterone simulations, patients who were simulated as receiving nilotinib were 
assumed to have a light fat meal and possibly just a glass of grape juice 2 hours before or 
1 hour after nilotinib was taken. An 18% reduction in apparent clearance was introduced 
to reflect this food effect (Tanaka et al., 2010; Yin et al., 2010).   
2.3 Study Design 
Patients in the simulated abiraterone trials were randomly assigned to take 1,000 
mg once daily and patients in the simulated nilotinib trials were assigned to take a 300 or 
400 mg tablet twice daily in 1:1 fashion.  Virtual pharmacokinetic samples for each 
patient were assumed to occur at week 1, week 4, and month 2 and month 3 based on a 
previously established trial sampling schedule (see Figure 5.1) after the start of the trial 
so each individual had a total of 4 measurements (one sample obtained on each occasion). 
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This sampling schedule was designed to fit in with the standard clinical follow up of the 
patient. The samples were assumed to occur at random times during clinic hours.  The 
visit day for each pharmacokinetic sample of each hypothetical patient was randomly 
selected from a discrete distribution with 50% of virtual patients having a visit sample 
drawn on the recommended day, 20%   1 day, 20% at  2 days and 10% at  3 days 
from the scheduled visit date.  Each clinic visit time was randomly selected from a 
uniform distribution assuming regular office hours from 7am to 6pm.  To mimic food 
intake when patients take their medications, a random food covariate was generated for 
each hypothetical patient and sampled for the four different clinic visit occasions within 
each patient.   
The hypothetical patients were assigned into trial sizes of 20, 50 or 70 individuals, 
and each trial was replicated 100 times. The same study design was tested using three 
different between-occasion variability levels: 10, 25, and 40% CV on drug clearance. 
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Figure 5.1. Study schema of abiraterone and nilotinib clinical trials. 
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2.4 Population Pharmacokinetic Model Estimation 
The population pharmacokinetics of the hypothetical patients in each trial were 
analyzed using nonlinear mixed effect modeling software, NONMEM, Version VII 
(GloboMax_LLC, Ellicott City, MD, USA) using Wings for NONMEM, Version 7. One-
compartment structural model with a proportional residual error model was tested using 
the first-order conditional estimation (FOCE) method. Between-individual variability was 
tested on oral clearance and volume of distribution, and between-occasion variability was 
tested on oral clearance only. The between-individual and between-occasion variability 
for Pop PK parameters were assumed to be log-normally distributed and evaluated using 
an exponential model  Pi,k = PTV x e
ηp,i
 x e
ηp,k
 where Pi,k is the parameter estimate for the i 
th
  individual after the k 
th
  dose administered and PTV is the typical value for the parameter 
at the population level. The variability between the i 
th
 individual and the population 
parameter value was described by p,i which was identically distributed with a mean of 0 
and a variance of  ωη p,i 
2
 (Feng et al., 2006). The variability between the k 
th
 occasion of 
dose administration and the population parameter value was described by p,k which was 
identically distributed with a mean of 0 and a variance of ωη p,k 
2
.  In addition to the 
between-individual and between-occasion variability, residual variability was described 
by a proportional error model. That is, )1(ˆ ijijij yy  where ijy and ijyˆ are the j 
th
  
observed nilotinib or abiraterone concentration and its corresponding model predicted 
concentration, respectively, with the difference described by 
ij which is assumed to be 
normally distributed with a mean of 0 and a variance of 2. In order to estimate between-
occasion variability in the model, the residual error was fixed in the estimation step.  
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2.5 Evaluation of Clinical Trial Designs 
The food effect in each trial was evaluated by comparing the fit of a base model 
with no food effects with a model that includes a food effect covariate on oral clearance. 
The model comparison was based on a likelihood ratio test using the objective function 
value (OFV) from NONMEM. The change in the OFV returned by NONMEM is 
approximately equal to -2 x log likelihood. The difference in -2 x log likelihood between 
two models that are nested follows a χ2 distribution. The significance level for identifying 
the food effect corresponded to a decrease in the OFV of greater than 6.63 (p-value 
0.01, df=1). The power to detect a food effect is the percent of the trials where the 
population PK analysis demonstrated significant OFV change among the 100 trials in 
both abiraterone and nilotinib and retrieving a food effect value within 20% of the true 
food effect value.    
In addition, to determining whether or not a food effect was detected by the trial 
design, the accuracy and precision of the model for retrieving parameter values of 
clearance, between-individual and between-occasion variability was assessed using two 
statistical standard criteria: percent bias and percent precision (Huang et al., 2007).  
              At the population level, the bias of each parameter represents the difference 
between the estimated values from the simulated (true) value of the population, and the 
percent bias is the mean predicted error normalized by the simulated value taken from the 
literature. The bias is calculated using the equation shown below: 
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where Yp,J  is the predicted value for the j 
th
  trial in total m trials with the same given 
between-occasion variability level and the same sample size, and Ye is the literature value 
we simulated from. The precision was estimated by calculating the root mean square 
error, reflecting the distribution of variance, and the percent precision is the root mean 
square error normalized by the simulated mean.  This included the bias and precision of 
the estimation of the food effect.   
            
Parameter estimates at the individual level were evaluated using percent bias and percent 
precision.       
    
where      and      are the predicted and simulated values for the  
   patient, respectively. 
n represents the number of patients in the trial.                                                                                          
           
Then, an average of individual percent bias and precision of the m number of trials was 
calculated.  
3. Results 
         The goodness-of- fit plots for the final model were shown in Figure 5.2 and 5.3 for 
abiraterone and niltonib, respectively. The percent bias and precision for the population 
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oral clearance for abiraterone ranged from -37% to -31% and 36.2% to 38.1%, 
respectively (Table 5.3). The average percent bias and precision are noticeably smaller in 
magnitude for individual clearance estimates (range of 1.2% to 4.4% and 14.5% to 19.9%, 
respectively). This indicates that the model estimates for oral clearance are more accurate 
and less variable at the individual level compared to the population level. Across three 
between-occasion variability levels (10, 25, and 40%), 21%, 10% and 11% of the 
abiraterone trials, respectively, retrieved population clearance values within 20% of the 
true value. The ranges of percent bias and precision for between-individual variability 
were -45.1% to-42.1% and 42.8% to 45.9%, respectively, with minimal variations with 
number of patients in the trial or between-occasion variability. The ranges of percent bias 
and precision of between-occasion variability were -30% to -1.1% and 11.6% to 40.7%, 
respectively.  There was a decrease in both the between-occasion variability bias and 
precision as the number of patients and between-occasion variability increased. The 
known food effect on oral clearance for abiraterone was identified in 100% of simulated 
trials with 20, 50 and 70 patients for the 10%, 25%, and 40% between-occasion 
variability levels. The ranges of percent bias and precision of food effect were 2.01% to 
4.42% and 6.81% to 14.4%, respectively. 
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Figure 5.2. Goodness-of-fit plots for the final model of abiraterone.  
Plot of population and individual predicted versus observed concentrations and plot of conditional 
weighted residuals versus population predicted concentrations and time (hours). 
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Figure 5.3. Goodness-of-fit plots for the final model of nilotinib.  
Plot of population and individual predicted versus observed concentrations and plot of conditional 
weighted residuals versus population predicted concentrations and time (hours). 
 
 
 
 
 
      Table 5.3.  Bias and precision of abiraterone oral clearance at the population level and individual level, between-individual     
      variability, and between-occasion variability 
Between-
occasion 
variability 
Number of 
patients in 
trial 
Oral Clearance – 
Population level 
Oral Clearance – 
Individual level 
Between-individual 
variability 
Between-occasion 
variability 
Food effect 
  Bias Precision  Bias Precision Bias Precision Bias Precision Bias Precision 
10% 20 -32.3% 37.1%  1.5% 14.5% -44% 45.6% -30% 40.7% 2.65% 9.95% 
 50 -36.6% 37.8%  1.3% 14.6% -43.6% 44.5% -25.8% 30.8% 4.42% 7.42% 
 70 -36.8% 37.8% 1.4% 14.9% -43.3% 43.5% -15.3% 23.3% 3.84% 6.81% 
25% 20 -31.7% 36.6% 3.3% 19.6% -45.1% 45.9% -5.85% 18.8% 2.36% 11.8% 
 50 -36.3% 37.6% 1.2% 18.9% -42.4% 42.8% -5.51% 14.6% 4.16% 8% 
 70 -36.9% 37.9% 3.2% 19.9% -43 % 43% -3.08% 14.8% 3.61% 7.22% 
40% 20 -31% 36.2% 1.4%    19.7% -44.9% 46.1% -1.34% 17.4% 2.01% 14.4% 
 50 -35.7% 37.1% 1.6% 19.9% -42.1% 42.8% -1.44% 13.4% 2.52% 11.9% 
 70 -37% 38.1% 4.4% 19.6% -42.6% 43% -1.11% 11.6% 2.64% 8.6% 
1
0
4
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The percent bias and precision on the population oral clearance for nilotinib ranged from 
-13.3% to -11.8% and 14.2% to17.0%, respectively (Table 5.4) and were consistent 
across between-occasion variability levels (10%, 25% and 40%). In contrast to 
abiraterone, the average individual nilotinib oral clearance estimates were significantly 
more accurate and precise than population estimates with the percent bias and precision 
ranging from -1.9% to -0. 5% and 4.2% to 8.6%, respectively. Across three between-
occasion variability levels (10, 25 and 40%), 86, 84 and 83% of the nilotinib trials, 
respectively, retrieved the population oral clearance within 20% of the true value. The 
ranges of percent bias and precision of between-individual variability were -9.9% to -7. 
9% and 11.3% to 19.4%, respectively and ranged from -3.9% to -0.4% and 4.9% to 
11.0% for percent bias and precision on between-occasion variability. Retrieval of the 
known food effect in this system was observed in 100% of the simulated nilotinib trials 
with 10% between-occasion variability with trial sizes of 25, 50, and 70 patients.  For 
nilotinib trials simulated with 25% between-occasion variability, significant food effects 
on oral clearance were retrieved in 80% of 20 patient trials, 99% of 50 patient trials, and 
100% of 70 patient trials. Nilotinib trials simulated with 40% between-occasion 
variability resulted in significant food effects on clearance being retrieved in 50% of 20 
patient trials, 78% of 50 patient trials, and 88% of 70 patient trials. The ranges of percent 
bias and precision of food effect were -2.16% to 11.8% and 6.3% to 38.8%, respectively 
 
 
 
      
         Table 5.4.  Bias and precision of nilotinib oral clearance at the population level and individual level, between-individual  
         variability, and between-occasion variability 
Between-
occasion 
variability 
Number of 
patients in 
trial 
Oral Clearance – 
Population level 
Oral Clearance – 
Individual level 
Between-individual 
variability 
Between-occasion 
variability 
Food effect 
  Bias Precision  Bias Precision Bias Precision Bias Precision Bias Precision 
10% 20 -11.8% 16.0% -0.6% 4.6% -9.0% 18.1% -3.9% 11.0% -0.12% 12.3% 
 50 -12.0% 16.3% -0.5% 4.3% -9.9% 13.4% -2.1% 6.9% -0.05% 12.3% 
 70 -12.8% 14.2% -0.5% 4.2% -8.0% 11.3% -2.3% 5.7% -0.04% 6.3% 
25% 20 -12.0% 16.2% -1.5% 6.6% -8.8% 18.5% -1.9% 8.9% -0.4% 30% 
 50 -12.4% 16.7% -1.0% 6% -9.1% 13.1% -1.2% 5.2% 0.9% 20.9% 
 70 -13.3% 14.7% -0.8% 5.7% -7.9% 11.7% -0.9% 4.9% -1.39% 15.5% 
40% 20 -12% 16.4% -1.9% 8.6% -8.5% 19.4% -1.8% 8.7% 11.8% 38.8% 
 50 -12.7% 17.0% -1.0% 7.2% -9.2% 13.9% -0.4% 7.7% 2.32% 30% 
 70 -13.3% 14.7% -0.9% 7.1% -7.9% 12.3% -0.7% 4.9% -2.16% 24.3% 
1
0
6  
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4. Discussion 
         Virtual clinical trials of abiraterone and nilotinib using sparse concentration 
measurements and a population PK sampling time design were simulated to test whether 
the drug exposure of each simulated patient and its variability under different prandial 
conditions on oral clearance for two recently approved drugs would be retrieved 
accurately and precisely.  The trial design is a typical phase II design in the NCI 
cooperative system and this assessment provides and evaluation of whether there is value 
in drawing sparse samples to utilize in population pharmacokinetic analysis for the 
determination of individual drug exposure. It was important to assess this particular study 
design as it is widely used and insight on the value of drug concentration sampling under 
these conditions was unclear.  Population as well as individual pharmacokinetic 
parameters for abiraterone, with a large food effect, and nilotinib, with a smaller food 
effect, were well estimated from the virtual trial results. This evaluation of whether 
between-individual and between-occasion variability can be well captured with a 
significant covariate effect on oral clearance (the underlying food effect) at different 
levels of variability on anticancer drug exposure is a novel observation. As the prior 
knowledge of more than 100% between-individual variability was introduced to oral 
clearance in the abiraterone trial, the model estimation of the population oral clearance 
parameter and between-individual variability have relatively poor percent bias and 
precision compared to the  nilotinib trial. This is reflected in the power calculation 
showing that only 10 to 20% of the trials across three between-occasion variability levels 
(10, 25, 40%) have population oral clearance estimates within 20% of the true value. This 
finding indicates that retrieving population level effects with large between-individual 
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variability may need a much larger trial size or more intense sampling schedule or a 
combination of both.  
         Between-occasion variability estimates were reasonable considering both percent 
bias and precision were less than 30% in most trial simulations. However, the percent 
bias and precision were relatively poor for the simulated abiraterone trials with 20 
patients and 10% within-individual variability. One possible explanation of this is that the 
system is less able to capture between-individual variability if the actual variability is 
small, but the true mechanism contributing to this poor bias at 10% between-individual 
variability is as yet unclear.  
         This model was unable to estimate both residual error and between-occasion 
variability accurately simultaneously. In order to accurately capture the between-
individual variability, the residual error estimation was fixed to published values.  This 
suggests that more than one sample per occasion will be required to distinguish these 
hierarchies of variability simultaneously.  
         The effects of two important features of such clinical trials were quantified using a 
NONMEM based simulation analysis.  These were the power to detect differences in oral 
drug clearance related to the prandial state of the study participants and the degree of 
between-individual variability and sample size. When the between-individual variability 
was set to 25% for a trial with 20 patients, 80% of the simulated nilotonib trials resulted 
in the detection of a statistically significant reduction in oral clearance caused by the food 
effect. The power to detect this food effect on oral drug clearance increased to 100% 
when the number of patients per trial was increased from 20 to 70. At 40% between-
individual variability, the food effect signal was observed in only 50% of trials with 20 
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patients, increasing to 88% when the number of patients increased to 50. The percent 
precision also indicated that the food effect as a covariate was captured less precisely 
when between-occasion variability increased, and the trial sample size was reduced. In 
contrast, abiraterone with a much more substantial food effect (92% reduction in oral 
clearance) resulted in a power to detect the food effect of 100% in the smallest trial 
evaluated (20 patients).  This virtual trial also had 40% between-individual variability 
and resulted percent bias and precision on the Pop PK parameters that were all less than 
20%. Using a modeling approach, we were able to simulate a complex clinical oncology 
population pharmacokinetic trial setting and capture the between-occasion variability and 
the magnitude of individual drug exposure in the presence of a large food effect for two 
recently approved oral anti-cancer agents. This simulated approach facilitated an early 
evaluation of the proposed trial design. However, clinical trial simulations are generated 
based on many trial assumptions, and these assumptions may include uncertainty. In fact, 
with different underlying assumptions, the simulated outcomes can differ, so multiple 
scenarios as well as assumptions must be tested in order to fully interpret the relevance of 
the results.  
         There are limitations to this analysis. First, a dropout model was not incorporated in 
this study design which can potentially contribute to censor events in a 3 month study. 
The simulations also assumed parameter distributions based on available food effect 
assessment in previous non-compartmental analysis. Because of the established sampling 
schedule, both drugs were better estimated with a simplified model structure.  Despite 
this, the model provides an approximation of the actual behavior and can capture the 
trend of the variability within the population. In fact, this simplified modeling approach 
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was previously proposed to assess the pharmacokinetics of some drug entities in the trials 
with a relative sparse sampling schedule (Scerwin et al., 2012; van Erp et al., 2011). The 
sampling schedule could also be optimized for the identification of food effects and 
model parameters, but the objective of this work was to evaluate trial designs given a 
commonly used sampling schedule. Second, non-compliance was not considered in this 
study design as we assumed that the compliance rate should be reasonably controlled in 
the clinical trial although this will result in a higher residual error and between-individual 
variability than compliance accounted for using electronically monitoring (Vrijens et al., 
2005). This study emphasizes the importance of addressing trial designs where intensive 
sampling cannot be obtained and yet there is a need to understand the drug exposure 
characteristics to what are otherwise medications with highly variable pharmacokinetic 
disposition.    
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CHAPTER VI: Genetic determinants of vincristine neuropathy in pediatric acute 
lymphoblastic leukemia patients  
1. Introduction 
         Vincristine is one of the most commonly prescribed anticancer agents, and it has 
been used to treat a wide variety of malignancies. Even though the drug is commonly 
used, the dose optimization of vincristine and potential causes of severe side effects and 
lack of efficacy still remain unclear. In fact, vincristine plays a role in many cellular 
mechanisms. It not only binds irreversibly to microtubules and spindle proteins and 
interferes with the formation of the mitotic spindle, but also depolymerizes microtubules 
and may also interfere with amino acid, cyclic AMP, and glutathione metabolism. In 
addition, it is associated with calmodulin-dependent Ca++ -transport ATPase activity, 
cellular respiration, and nucleic acid and lipid biosynthesis (National Cancer Institute, 
2011). 
         Similar to other chemotherapy agents such as taxanes and platinums, vincristine is 
associated with highly variable cumulative dose-dependent neurotoxicity, secondary to its 
binding to tubulin dimers, which can inhibit the assembly of microtubule and arrest 
mitosis in metaphase (Park et al., 2013; Howlader et al., 2012; Verstappen et al., 2005; 
Postma et al., 1993; Haim et al., 1994). In severe cases, neurotoxicity may lead to dose 
reduction, which may negatively impact the drug efficacy. In addition, substantial 
variability in vincristine pharmacokinetics with up to a 40-fold interpatient variation has 
been reported in the literature (Crom et al., 1994; de Graaf et al., 1995), and this 
pharmacokinetic variability may be associated with severity of neurotoxicity. Published 
data also indicate that vincristine pharmacokinetics may in fact be associated with long-
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term outcomes in children of acute lymphoblastic leukemia with rapid clearance being 
associated with a greater risk of relapse. (Lonnerholm et al., 2008). 
The variability of vincristine pharmacokinetics might be potentially explained in part by 
genetic differences in cytochrome P450 3A family enzymes, which are important for 
vincristine metabolism (Dennison, et al., 2006).     
         As previous study shown, Caucasian children with ALL more commonly suffer 
from vincristine-induced peripheral neuropathy (VIPN) than do children of other 
ethnicities due to CYP3A5 genotype (Dennison et al., 2006). In fact, another study 
suggests that polymorphisms of multi-drug resistance (MDR1) gene which code as an 
efflux transporter are associated with peripheral neuropathy (Te Loo et al., 2010). This 
might also contribute to the variability of vincristine PK, and the genetic impact on drug 
toxicity. In addition, study published by Hertz et al. suggested that CYP2C8 
polymorphisms can increase the risk of neuropathy in breast cancer patients treated with 
paclitaxel (Hertz et al., 2013). This indicated that in the case of paclitaxel drug toxicity 
may be associated with pharmacokinetic exposure through metabolic pathways. However, 
those findings are controversial across studies with limited validation in the literature 
(Hertz et al., 2014).  In a study of 329 subjects by Broyl et al., an early-onset vincristine-
induced neuropathy was characterized by the up-regulation of genes involved in cell 
cycle and proliferation, including AURKA and MKI67, and also by the presence of 
single-nucleotide polymorphisms (SNPs) in genes involved in these processes, such as 
GLI1 (rs2228224 and rs2242578) (Broyl et al.,2010). Similar to the vincristine 
association analyses, many studies have aimed to identify potential genetic risks in 
predicting neuropathy induced by platinum agents or Taxanes. In those genomic studies, 
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few candidate genes (FGD4, TUBB2A, ARHGEG and PRX) were found to be associated 
with paclitaxel-induced peripheral neurotoxicity. These results indicated that drug- 
induced peripheral neurotoxicity may share genetic roots as hereditary neuropathies 
(Baldwin et al., 2012; Leandro-Garcia et al., 2012; Beutler et al., 2014; Travis et al., 
2014).  Furthermore, McWhinney- Glass’s group further explored genetic risk of four 
SNPs (SOX10, BCL2, OPRM1 and TRPV1) in an association analysis of 
platinum/taxane-induced neurotoxicity. Interestingly, a cumulative association of these 
genetic variations with neurotoxicity was observed in this population of 404 patients with 
ovarian disease (McWhinney-Glass et al., 2013). 
         In order to better understand VIPN and predict risk for toxicity to ultimately aid in 
vincristine  dose optimization and to further explore the findings from the previous 
studies, a genome-wide association analysis was proposed to take an unbiased  approach 
in evaluating the  association between germline variants and VIPN in pediatric ALL 
patients. Indeed, as the genomics technologies improve, genetic biomarkers provide a 
unique tool for prediction of disease outcomes of interest. The objective of this study is to 
build a candidate gene list including polymorphisms associated with VIPN from the 
GWAS study as well as other association analysis approaches. The rationale for the 
proposed research is that once we understand the impact of specific pharmacogenetic 
changes on vincristine toxicity, we will be able to use this information to optimize dosing 
of this important drug for individual patients. 
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2. Materials and Methods 
2.1 ALL Patient Population and Study Design 
         A total of 2154 children with precursor B cell acute lymphoblastic leukemia from 
the Pediatric Oncology Group (POG) 9904, 9905 and 9906 trials were enrolled.  In 
conjunction with 9905, the objective of the 9904 trial was to determine if a delayed multi-
drug intensification, administered in the context of intensive anti-metabolite therapy 
improved outcomes and compare the different durations of methotrexate infusion. 9906 
was aimed at specifically evaluating patients at high risk for treatment failure. Those who 
had Down’s syndrome, Charcot Marie Tooth disease, baseline peripheral neuropathy, or a 
history of liver disease with chronic elevation in liver function tests to greater than 5-
times the upper limit of normal based on normal values for age were excluded from this 
GWAS. Genotyping of germline samples from 1888 patients on the 9900 trials has been 
completed using the Affymetrix GeneChip Human Mapping 6 and 500K arrays for 9904/ 
9905 and 9906, respectively.  The number of vincristine doses per patient over the course 
of treatment ranged from 18-23, depending on specific protocol and treatment arm. 
Standard vincristine dosing of 1.5mg/m
2
/ dose was used. The complete treatment 
duration is 2.5 years from the date of diagnosis for females and 3.5 years for males. The 
treatment plan is summarized in Figure 6.1.  
 
 
  
 
 
 
     Vincristine dose regimen scheme in POG 9904 trial 
 
              
 
 Vincristine dose regimen scheme in POG 9905 trial 
 
 
 
 
 
 
 
Day 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127 134 141 148 155 162 169 176 183 190 197 204 211 218 225 232 239 246 253 260 267 274
INDUCTION                                                               CONTINUATION CONTINUTATION DELAYINTENSIFICATION
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
9904 GroupA V V V V V V V V VV
GroupB V V V V V V V V VV
GroupC V V V V V V V V V V V
GroupD V V V V V V V V V V V
Day 281 288 295 302 309 316 323 330 337 344 351 358 365 372 379 386 393 400 407 414 421 428 435 442 449 456 463 470 477 484 491 498 505 512 519 526 533 540 547 554
Week 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
9904 GroupA VV VV VV
GroupB VV VV VV
GroupC VV VV VV
GroupD VV VV VV
Day 561 568 575 582 589 596 603 610 617 624 631 638 645 652 659 666 673 680 687 694 701 708 715 722 729
Week 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
9904 GroupA VV VV
GroupB VV VV
GroupC VV VV
GroupD VV VV
Day 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127 134 141 148 155 162 169 176 183 190 197 204 211 218 225 232 239 246 253 260 267 274
INDUCTION                                                               CONTINUATION INTENSE CONTINUTATION
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
9905 GroupA V V V V V V V V V
GroupB V V V V V V V V V
GroupC V V V V V V V V V
GroupD V V V V V V V V V
Day 281 288 295 302 309 316 323 330 337 344 351 358 365 372 379 386 393 400 407 414 421 428 435 442 449 456 463 470 477 484 491 498 505 512 519 526 533 540 547 554
Week 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
9905 GroupA V V V
GroupB V V V
GroupC V V V V
GroupD V V V V
Day 561 568 575 582 589 596 603 610 617 624 631 638 645 652 659 666 673 680 687 694 701 708 715 722 729 736 743 750 757 764 771 778 785 792 799 806 813 820 827 834
Week 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
9905 GroupA V V V V
GroupB V V V V
GroupC V V V
GroupD V V V
Day 841 848 855 862 869 876 883 890 897 904
Week 121 122 123 124 125 126 127 128 129 130
9905 GroupA
GroupB
GroupC V
GroupD V
1
1
5
 
  
 
 
 
 
 
       Vincristine dose regimen scheme in POG 9906 trial 
      Figure 6.1. Vincristine dosage regimens for POG 9904, 9905 and 9906 trials. 
 
 
 
  
 DELAYED INTENSIFICATION- RECONSOLIDATION
Day 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 127 134 141 148 155 162 169 176 183 190 197 204 211 218 225 232 239 246 253 260 267 274
INDUCTION CONTINUTATION INTERIM MAINTENANCE  DELAYED INTENSIFICATION- REINDUCTION
Week 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
9906 V V V V V V V V V V V V V V V V V V V V V V V V V
Day 281 288 295 302 309 316 323 330 337 344 351 358 365 372 379 386 393 400 407 414 421 428 435 442 449 456 463 470 477 484 491 498 505 512 519 526 533 540 547 554
Week 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
9906 V V V V V V V V V V V V
Day 561 568 575 582 589 596 603 610 617 624 631 638 645 652 659 666 673 680 687 694 701 708 715 722 729 736 743 750 757 764 771 778 785 792 799 806 813 820 827 834
Week 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
9906 V V V V V V V V V V
Day 841 848 855 862 869 876 883 890 897 904
Week 121 122 123 124 125 126 127 128 129 130
9905 V V
1
1
6
 
                                                                          117 
 
2.2 Genotype Data and Quality Control 
             DNA(500ng) was digested with restriction enzymes, amplified, labeled, and 
hybridized to the Affymetric GeneChip Human Mapping  6 set for P9004 and 9005 and 
500K for 9006. The genotypic data included raw data files, genotypes, quality scores, 
intensity values, SNPs and sample summary tables. QC was performed to remove both 
samples and markers which were unreliable in the following fashion. Samples with >5% 
missing rate were excluded. Furthermore, SNPs with a study-wide missing data rate of 
>5% and/or evidence of Hardy-Weinberg disequilibrium (p≤ 0.0001) were discarded. 
SNPs with minor allele frequency (MAF) of <0.05 were also removed from the analysis 
because previous studies have shown that these SNPs have little power to detect 
association and are more prone to genotypic errors resulting in false positive evidence of 
association. In addition, MAF < 0.10 cutoff was applied for the recessive model in the 
analysis. PLINK was proposed to manipulate the data by generating both per sample and 
per SNP metrics to assess the quality of the genotypic data (Purcell et al., 2007). 
2.3 Population Stratification 
             A principal components approach (Price et al., 2006) was applied to correct for 
any possible stratification errors. A subset of the genome-wide SNP data was used to 
identify components that reflect population structure. Scores for each individual from 
the initial principal component assessment were calculated and included as covariates in 
the subsequent association analyses. 
2.4 Phenotype Identification 
             Vincristine is associated with highly variable cumulative dose-dependent 
peripheral neurotoxicity that often necessitates chemotherapy dose reductions, thereby 
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compromising efficacy. To do this association analysis, the first step was to define our 
phenotype of interest. National Cancer Institute Common Terminology Criteria for 
Adverse Events, version 3.0 (CTCAE v3.0) was used to capture and grade adverse events 
in this study. We defined neuropathy for the purposes of this analysis as any sensory or 
motor neuropathy  grade 2. Neuropathic pain was also captured in this study. For the 
purpose of this analysis, we designate neuropathic pain as secondary neuropathy as any 
sensory neuropathy, motor neuropathy or neuropathic pain   grade 2. 
2.5 Genome-Wide Association Study 
         The analysis started with association analysis of genotype frequencies with primary 
neuropathy (CTCAT V3.0 sensory or motor neuropathy). Neuropathy was treated as a 
binary variable; ie, 1 for having neuropathy and 0 for no neuropathy.  Clinical, 
demographic, and population stratification variables were tested as covariates in the 
regression analyses. Genotype frequencies were tested in dominant, recessive and 
additive (gene-dose) model. This strategy was also used to test the association between 
SNPs and secondary neuropathy. These analyses were performed in R coxph package 
(Therneau et al., 2014). The corresponding p-value of each SNP was summarized across 
chromosomes in Manhattan and QQ plots.  
2.6 Gene Enrichment Analysis  
              The gene enrichment analysis was done by focusing on enrichment of specific 
target genes (Shamir, 2010). In this case, the target genes are genes previously identified 
as being related to neuropathy or pain. The initial step of the analysis was to obtain SNP 
rsIDs along with their genomic positions and p-value from the SNP6.0 Affymetrix COG 
data which was previously analyzed in the survival analysis with neuropathy phenotype. 
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SNPs were annotated with their respective genes using their positions and with the 
annotation file from UCSC genome browser. This was done by matching the SNP 
chromosome number with the gene chromosome number and then looking for SNPs that 
within the gene base pair co-ordinates.  Upstream or downstream regions of the genes 
were not considered. Using the significance frequency table, a Fisher’s exact test was run 
to calculate the odds ratio based on equation 1 for each gene.  
 
 
Odds Ratio = N11*N22/N12*N21 (Equation 1) 
N is the number of SNPs in each category. The p-value was estimated in Fisher’s extract 
test. Based on the criteria of p-value <0.05 from Fisher’s extract test and calculated odds 
ratio >1, genes which passed the criteria were selected. 
2.7 Pathway Analysis  
             Significant pathways in biological processes were identified in an interactive 
pathway analysis from Ingenuity systems (Ingenuity systems analysis). The following 
steps were used in the analysis: “(1) Genes identified as significant from the experimental 
data sets were overlaid onto the interactome. Focus genes we re-identified as the subset 
having direct interaction(s) with other genes in the database. (2) The specificity of 
connections for each focus gene was calculated by the percentage of its connections to 
other significant genes. The initiation and growth of pathways proceeded from genes with 
the highest specificity of connections. Each pathway had a maximum of 35 genes. (3) 
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Pathways of highly interconnected genes were identified by statistical likelihood using 
the following equation: 
Score=-log10(  ∑
  (     (        
 (    
   
     
where N is the number of genes in the genomic network, of which G are focus genes, for 
a pathway of genes, f of which are focus genes, and C (n,k) is the binomial coefficient. (4) 
Pathways with a score greater than 4 (P < 0.0001) were combined to form a composite 
network representing the underlying biology of the process.”  
2.8 Gene Expression Analysis  
             Gene expression omnibus(GEO) is a public functional genomics data repository 
supporting MIAME-compliant data submissions (Lehnhardt et al.,2005). To explore 
whether the gene expression level was changed after treating with vincristine, a keyword 
search of vincristine in GEO database was performed. SNPs in COG data were annotated 
with their respective genes using their positions and with the annotation file from UCSC 
genome browser. These genes were compared with the genes in GEO. Those overlapped 
genes were further filtered by the gene expression level with a threshold of greater than 
50% up-regulation or down-regulation of the vincristine treated replicates compared to 
the control. For those genes which passed the threshold, the SNPs with their p-values 
from the GWAS study were evaluated and visualized in the QQ plot.  
2.9 eQTL(GTEx) Analysis  
             In addition to the GEO database, tissue data from GTEx (Genotype-Tissue 
Expression) project (Gibbs et al., 2010) was explored to determine the correlations 
between genotype and the tissue-specific gene expression level. This could help to 
identify the expression quantitative trait locus (eQTL) that might regulate the expression 
level of mRNAs or proteins. Based on the available data from the published tissue bank, 
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four of the brain tissues including cerebellum, frontal cortex, temporal cortex and pons 
were considered in the correlation analysis with neuropathy. 
3. Results 
3.1 ALL Patient Characteristics 
             Within 2154 ALL patients enrolled in POG 9904, 9905 and 9906 trials, 
genotyping of 1888 individuals were eligible. To further insure the genotyping quality, 
only patients from POG 9904 and 9905 who were genotyped using Affymetrix 6.0 were 
included in the initial analysis. Furthermore, a principle component approach was applied 
to correct the population stratification error by using Hapmap references of Han Chinese 
in Beijing, China (CHB), Utah residents with Northern and Western European ancestry 
from the CEPH collection (CEU) and African ancestry in Southwest USA (ASW). Based 
on the result of the two principal component analyses (PC1 and PC2) in Figure 6.2, 
Caucasians were better overlapped with the reference and represented the majority of the 
population. In addition, data which did not pass the additional quality control including 
samples or SNP with >5% missing data rate and/or evidence of Hardy-Weinberg 
disequilibrium (p≤ 0.0001) and/or MAF <0.05 for dominant and additive model and/or 
MAF< 0.10 for recessive model were excluded, and a total of 587,014 SNPs of 1068 
individuals remained in the analysis (Figure 6.3).  
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Figure 6.2. Flowchart of ALL patient selection in the final GWAS analysis. 
MAF: minor allele frequency; dom: dominant model; add: additive model; rec: recessive model; 
HW: Hardy Weinberg equilibrium.  
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Figure 6.3. Population stratification using principal component analysis. 
HapMap reference was used to compare the data. CHB: Han Chinese in Beijing, China. 
CEU:Utah residents with Northern and Western European ancestry from the CEPH. ASW: 
African ancestry in Southwest USA. 
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3.2 Identification of Genomic Loci Associated with ALL Neuropathy Risk in GWAS  
Analysis 
       The initial step of the analysis coded homozygous major alleles, heterozygous, and 
homozygous minor alleles as 0, 1 and 2, respectively using PLINK. After the data was 
manipulated, a Cox proportional hazard model was performed to test association between 
markers and the primary and the secondary neuropathy in three genetic models. The p-
values in –log10 were shown across chromosomes in Manhattan plot and QQ plot for 
primary neuropathy and secondary neuropathy in Figure 6.4 A, B, C, D, E and F and 
Figure 6.5A, B, C, D, E and F, respectively. 
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      A                                                                   B
                                                                          
      C                                                                  D 
 
       E                                                                 F 
 
Figure 6.4. Manhattan plot and QQ plot of GWAS association analysis with primary 
neuropathy.  
A and B: dominant model; C and D:  recessive model; E and F: additive model. 
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       A                                                                B   
 
      C                                                                  D   
 
       E                                                                 F   
     
Figure 6.5. Manhattan plot and QQ plot of GWAS association analysis with secondary 
neuropathy.  
A and B: dominant model; C and D:  recessive model; E and F: additive model. 
 
     
 
 
 
 
                                                                          127 
 
     In order to determine the candidate SNPs for validation, a threshold of p-value of 
1x10
-4
 was selected. Those candidate SNPs with p-value < 1x10
-5
 were further 
investigated and identified the location of gene region and visualized closely in zoom-in 
plot (Figure 6.6).  A total of 23 genes were identified across both neuropathy phenotypes 
and three genetic model structures. The rsID, position, minor allele, MAF and hazard 
ratio of those candidate SNPs as well as its corresponding gene were summarized in 
Table 6.1.  
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Gene Zoom-in plot Corresponding SNPs 
 
 
 
 
 
NEK6 
 
 
 
 
 
 
 
 
 
ZFPM2 
 
 
 
 
 
 
 
 
 
FHIT 
 
 
 
 
 
 
 
MICAL3 
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CNTNAP2 
 
 
 
 
 
 
 
 
 
 
ZNF365 
 
 
 
 
 
 
 
 
 
 
PDE8B 
 
 
 
 
 
 
 
 
 
 
 
LPPR5 
 
 
 
 
 
 
 
 
 
 
 
 
GRM8 
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CSNK1G3 
 
 
 
 
 
 
 
 
 
 
 
 
NOD1 
 
 
 
 
 
 
 
 
 
ERLEC1 
 
 
 
 
 
 
 
 
 
PRKG1 
 
 
 
 
 
 
 
 
 
 
 
PHACTR1 
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NDUFAF2 
 
 
 
 
 
 
 
 
 
 
 
ERCC8 
 
 
 
 
 
 
 
 
 
 
ELVOL7 
 
 
 
 
 
 
 
NAALADL2 
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Figure 6.6. Zoom-in plots of each candidate gene from GWAS study and their 
corresponding SNPs. NE:neuropathy( primary neuropathy); NEP:neuropathy and  neuropathic 
 
 
 
 
 
ACTN2 
 
 
 
 
 
 
 
 
 
 
 
 
TDRD1 
 
 
 
 
 
 
 
 
 
 
 
CADPS2 
 
 
 
 
 
 
 
 
 
 
 
 
 
FGF12 
 
 
 
 
 
 
 
 
 
 
 
 
MROH2A 
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pain (secondary neuropathy); DOM: dominant model; REC: recessive model; DOSE: additive 
model. 
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Table 6.1. Candidate genes selected from GWAS study.  
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3.3 Identification of Genomic Loci Associated with ALL Neuropathy Risk in Gene- 
Enrichment Analysis 
         A gene-enrichment analysis based on a bottom-up approach was conducted to 
explore genes previously identified as drug targets for treating neuropathy or pain. A total 
of 101 genes were identified for evaluation in this analysis. Among these 101 target 
genes, the SNPs were enriched in the gene regions were tested using Fisher’s extract test. 
The threshold of significance was set to be p-value at 0.05. A total of eight genes 
including CACNA1D, SLC29A4, CACNA1C, GRIK1, SCN8A, CACNB1, GRIN3A and 
SLC22A1 with odds ratio greater than 1 were identified and listed in Table 6.2. The 
zoom-in plots of those genes with their p-values were summarized in Figure 6.7. 
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Table 6.2. Candidate genes selected from gene-enrichment analysis. 
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Gene 
 
 
P-value 
 
Odds ratio 
 
Zoom-in plot 
 
 
 
 
 
CACNAID 
 
 
 
 
 
2.96E-10 
 
 
 
 
 
4.405549 
 
 
 
 
 
 
SLC29A4 
 
 
 
 
 
0.000133 
 
 
 
 
 
24.02168 
 
 
 
 
 
 
CACNA1C 
 
 
 
 
 
0.004477 
 
 
 
 
 
1.894156 
 
 
 
 
 
 
GRIK1 
 
 
 
 
 
0.008791 
 
 
 
 
 
 
 
 
 
2.109875 
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SCN8A 
 
 
 
 
 
0.016998 
 
 
 
 
 
2.746166 
 
 
 
 
 
 
CACNB1 
 
 
 
 
 
0.024969 
 
 
 
 
 
19.22312 
 
 
 
 
 
 
GRIN3A 
 
 
 
 
 
0.038966 
 
 
 
 
 
2.089492 
 
 
 
 
 
 
SLC22A1 
 
 
 
 
 
0.045554 
 
 
 
 
 
4.805872 
 
 
Figure 6.7. Zoom-in plots of each candidate gene from Gene enrichment analysis study and 
their corresponding P-value and odds ratio.  
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3.4 Pathway Identification of Genomic Loci Associated with ALL Neuropathy Risk 
         The candidate genes selected from the association analysis were further evaluated in 
an interactive pathway analysis. Only one pathway, pregenolone biosynthesis, passed the 
p-value threshold. In addition, two networks were selected based on the score that the 
system calculated.  The first network had a score of 35 with 14 focus moles including 
ACTN2, CNTNAP2, CSNK1G, ERCC8, ERLEC1, FGF12, GRM8, MICAL3, 
NAALADL2, NDUFAF2, NEK6, NOD1, PHACTR1 and TDRD1; it is cell-to cell 
signaling and interaction, infectious disease, inflammatory (Figure 6.8). The second 
network with a score of 15 with 7 focus moles including CADPS2, ELOVL7, FHIT, 
LPPR5, PDE8B, PRKG1 and ZFPM2  is tissue development, tumor morphology, cancer 
(Figure 6.9). 
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Figure 6.8. The network of cell-to cell signaling and interaction, infectious disease and 
inflammatory.   14 genes included ACTN2, CNTNAP2, CSNK1G, ERCC8, ERLEC1, FGF12, 
GRM8, MICAL3, NAALADL2, NDUFAF2, NEK6, NOD1, PHACTR1 and TDRD1 were 
identified in this network.  
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Figure 6.9. The network of tissue development, tumor morphology and cancer.                                                     
7 genes including CADPS2, ELOVL7, FHIT, LPPR5, PDE8B, PRKG1 and ZFPM2 were 
identified in this network. 
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3.5 The Change in Gene Expression of Genomic Loci Associated with ALL 
Neuropathy Risk 
         The correlation of genetic information and toxicity was further evaluated at the 
gene expression level to consider whether the genes of interest are functional and 
expressed.  A study of a fibrosarcoma cell line response to various cytostatic drugs was 
utilized in which the control cell line was compared to that (Figure 6.10). The gene 
expression level of the sample treated with vincristine was normalized by the control. A 
total of 4619 and 16893 SNPs reached the threshold of greater than 50% down-regulation 
and up-regulation, respectively. Based on the QQ plots, most of the p-values of SNPs 
were shown to approximately lie on the line y = x meaning that the p-values of the SNPs 
are likely to be randomly distributed.  Few SNPs were deviated from the line y=x. These 
are summarized in Figures 6.11 and 6.12 with their corresponding genes. 
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Figure 6.10. Fibrosarcoma cell line response to various cytostatic drugs in the GEO database. 
The cell line was treated with Vincristine, doxorubicin or actinomycin. 
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Figure 6.11. QQ-plots of genomic loci associated with ALL neuropathy risk in fibrosarcoma 
cell line. 
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Figure 6.12. Genes and corresponding SNPs of genomic loci associated with ALL 
neuropathy risk in fibrosarcoma cell line 
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3.6 Genomic Loci Associated with ALL Neuropathy Risk in Genotype-Tissue 
Expression eQTL 
         In addition to the GEO database, the correlation was also tested in the GTEx 
database. In this database, mRNA expressions were estimated in the different tissues. 
Based on current available tissues in the database, this study was carried out to analyze 
data from four brain tissues which are potentially related to our phenotype of interest. 
After matching the SNPs between our data and the GTEx database, p-values of these 
matched SNPs were further visualized in QQ plots across three genetic models and two 
phenotypes in Figure 6.13. Similar to GEO strategy, the SNPs with deviated –log10 p-
values from the line y = x were selected. eQTLs can be described as being cis, where the 
genotyped marker is within 2 MB of the expressed gene, or trans, in which the genotyped 
marker is far away from the expressed gene or even on another chromosome (Gibbs et al., 
2010). The corresponding genes of the selected SNPs were based on the probe position 
where the gene expression level was measured in the original eQTL study.  As Figure 
6.14 showed, in the brain cerebellum tissue, rs10153783 was found to correlate to the 
gene expression of collectin sub-family member 11 (COLEC11) in the dominant model 
for both primary and secondary neuropathies. Another SNP, rs359436, is associated with 
hydroxysteroid (17-beta) dehydrogenase 4 (HSD17B4) gene expression in both dominant 
and additive models for the secondary neuropathy. 
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Figure 6.13. QQ-plots of genomic loci associated with ALL neuropathy risk in eQTL data of 
four brain tissues.  
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Figure 6.14.  Indirect association of ALL neuropathy risk with eQTL expression.  
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4. Discussion 
         Based on a previous study from Dennison and colleagues, they concluded that 
CYP3A5 expressers experienced less vincristine-induced peripheral neuropathy and had 
lower metabolic ratios compared to CYP3A5 non-expressers (Dennison, et al., 2006). 
This finding stimulates our interests in identifying potential genetic explanations for the 
difference in the pharmacokinetic exposures in a large population and identifying 
associations between genetic markers and drug-induced neuropathy. In fact, a subgroup 
of patients had to discontinue the treatment because of the severity of the neuropathy and 
its major impact on their quality of life. Even though this study focused on initial 
discovery of association, we believe that this might be useful to suggest an alternative 
therapy for those patients before administration of vincristine. In this genome-wide 
association study, we identified several genetic loci associated with an incidence of VIPN 
 grade 2.  Based on the top-ranked SNPs in Table 6.1, 23 genes were identified in the 
association with either the primary or secondary neuropathy.   
          Among these 23 genes, one example is CSNK1G3. CSNK1G3 (Casein kinase 1, 
gamma 3) is an isoform of a monomeric serine-threonine protein kinase. Casein kinase 
has been implicated in a wide range of signaling activities such as cell differentiation, 
proliferation and apoptosis. Sakurai et al. previously found that the percentage of CK1ε-
positive neurons and the expression level of CK1ε protein were increased in dorsal root 
ganglion and the spinal cord of the neuropathic mice (Sakurai et al., 2009). Another 
example is Nek6 (NIMA-related kinase 6).  As RNA interference depletion studies 
reported by Yin et al., Nek6 and family isoforms are required for cell cycle progression 
through mitosis. Nek6 together with Nek7 and 9 form a mitotically activated module, 
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which plays a role in mitotic progression and more specifically spindle organization. Loss 
of Nek6 can lead to failure of centrosome separation in prophase and formation of weak 
mitotic spindles with reducing microtubule density (Yin et al., 2003).  This modification 
of microtubule dynamic through the change of Nek6 expression can potentially lead to an 
association with neuropathy.  In addition, MICAL3 is microtubule associated 
monooxygenase, calponin and LIM domain containing, which is an important regulator 
for microtubule polymerization (Terman et al., 2002; Fischer et al., 2005). Furthermore, 
ERCC8 is excision-repair-cross-complementing group 8. A study has shown that 
mutations in ERCC8 are associated with Cockayne syndrome, which is characterized by 
some neurological abnormalities including dys- or demyelinating neuropathy (Ohnishi et 
al., 1987; Smits et al., 1982).  
         Additional eight genes were discovered in an association with neuropathy from the 
gene enrichment analysis. In these eight genes, three (CACNAID, CACNA1C, CACNB1) 
are calcium channel, voltage-dependent subunits, and one (SCN8A) is a sodium channel, 
voltage gated subunit (Bock et al., 2011; Tan et al., 2011; Samak et al., 2011;  Hori et al., 
2012; Kloiber et al., 2012; Yang et al., 2012; Soeiro-de-Souza et al., 2012; Burgess et al., 
1995).  In particular, the phenotypes of mice with a mutation in SCN8A gene were found 
to be consistent with a defect in a neuronal sodium channel expressed in motor neuron 
(Burgess et al., 1995). Another two genes are in the transporter category. One (SLC29A4) 
is an equilibrative nucleoside transporter 4, which catalyzes the reuptake of monoamines 
into presynaptic neurons (Duan et al., 2013; Barnes et al., 2006). Another (SLC22A1) is a 
solute carrier family 22 member 1 which is a polyspecific organic cation transporter in 
many organs for elimination of endogenous small organic cations and toxins (Koehler et 
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al., 1997). In addition, two glutamate receptor, ionotropic subunits (GRIK1, GRIN3A) 
were also identified in the analysis. These two receptors have a critical role in excitatory 
synaptic transmission and plasticity in the CNS (Braga et al., 2009; Kaminski et al., 2004; 
Gryder et al., 2003; Rogawski et al., 2003). They govern a range of physiological 
conditions including neurological disorders caused by excitotoxic neuronal injury, 
psychiatric disorders and neuropathic pain syndromes (Petroff et al., 2002). These can be 
potential targets for further understanding of VIPN mechanism.  
          In the gene expression analyses, the expression levels were changed over 50% in 
eleven genes when treated with vincristine in the fibrosarcoma cell line. Interestingly, 
two (MICAL3 and ERCC8) and one (CANA1C) of these eleven genes were previously 
identified in the association and gene enrichment analyses, respectively. These findings 
confirmed that these genetic variants altered the gene expression, and the changes in 
expression may lead to toxicity. Different to the GEO analysis, two genes (COLEC11 
and HSD18B4) found in the eQTL data were in a trans- association with the probe genes, 
and this indicated an indirect association with lipid biosynethsis. In fact, similar to what 
we observed in the pathway analysis, an association between VIPN and lipid biosynethsis 
mechanism was shown. 
         With the design of the analyses by using different association approaches, some 
direct or indirect associations between genomic variations and VIPN in children with 
ALL were identified. In the discovery phase of potential targets, we came across some 
similar correlations observed from different approaches which provided an additional 
confirmation of the findings. These findings could be clinical relevance given the 
widespread use of vincristine in treating childhood cancers. To validate these 
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observations, candidate genes will be sequenced, and the association between genomic 
variations and VIPN will be further examined in the sequencing data. 
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CHAPTERVII: Genetic signature to predict vincristine neuropathy and relapse in 
children with acute lymphoblastic leukemia  
1.Introduction 
         A genome-wide association study (GWAS) is an examination of many common 
genetic variants in different individuals to determine if any variant is associated with a 
trait, and a way for scientists to identify genes involved in human disease. This method 
searches the genome for small variations that occur more frequently in people with a 
particular disease than in people without the disease. Each study can look at hundreds or 
thousands of single-nucleotide polymorphisms (SNPs) at the same time. Researchers use 
data from this type of study to pinpoint genes that may contribute to a person’s risk of 
developing a certain disease. Typically, GWAS focuses only on associations 
between SNPs and traits. There has been an increasing interest in relating genetic profiles 
to survival phenotypes such as time to event. Because of high dimensionality of SNP data, 
there is a limitation of collinearity in fitting a prediction model such as the Cox 
proportional hazards model (Sohn et al., 2009).  To avoid the collinearity problem, 
several methods based on penalized Cox proportional hazards models have been 
proposed. One of the approaches that we used is a LASSO penalized Cox proportional 
hazard model (Tibshirani, 1997).  
         The benefit of using a LASSO approach, instead of other penalized regression 
Smodels, is that this approach allows shrinking coefficients of insignificant predictors to 
exact zero which can simplify the model building in selecting a complex signature. In 
addition, this approach may potentially improve the predictability of genetic biomarkers 
to drug-induced toxicity as well as drug efficacy and provide a comprehensive and 
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unique signature. The objective of the study is to apply an alternative modeling approach 
to evaluate genetic biomarkers in predicting vincristine-induced neuropathy and relapse 
in childhood acute lymphoblastic leukemia patients.  With this signature approach, a risk 
assessment of patients treated with vincristine can be further applied to distinguish the 
clinical outcome in a population based on the accuracy of the model performance and to 
provide clinically useful information to avoid unnecessary exposure to patients who are 
likely to experience severe toxicity but not benefit from the treatment. 
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Figure 7.1. Model strategies using the LASSO penalized regression approach. 
Model 1: demographic and clinical variables were tested in the LASSO model; Model 2: 
demographic, clinical variables and SNPs with p-value < 1x 10
-5
 from the previous univariate 
analysis were tested in the LASSO model; Model 3: demographic, clinical variables and SNPs 
with p-value < 1x 10
-4
 from the previous univariate analysis were tested in the LASSO model.  
Dom: dominant model; Rec: recessive model; Add: additive model. 
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2. Materials and Methods 
2.1 Acute Lymphoblastic Leukemia (ALL) Patient Population and Study Design 
             Children with precursor B cell acute lymphoblastic leukemia from Pediatric 
Oncology Group (POG) 9904 and 9905 trials treated with 1.5mg/m
2
/dose vincristine 
doses and other chemotherapy treatments were included in the analysis as a training data 
set. The number of vincristine doses per patient over the course of treatment ranged from 
18-23, depending on specific protocol and treatment arm. In this population, genotyping 
of germline samples from a total of 1068 subjects using an Affymatrix 6 assay remained 
in the analysis after a sequential data quality control including population stratification, 
sample and SNP missing call rate, Hardy-Weinberg disequilibrium and minor allele 
frequency. The details of data quality control were described in CHAPTER VI (Fareed 
et al., 2013). In addition, genotyping and clinical data of 122 ALL subjects from POG 
9906 trial were used as a validation data set. 
2.2 Phenotype Identification 
         As an extension to the association studies between genomic variations and 
vincristine-induced neurotoxicity in Chapter VI, this study continually evaluated and 
focused on both primary and secondary neuropathy as toxicity endpoints.  The definition 
of the primary neuropathy based on National Cancer Institute Common Terminology 
Criteria for Adverse Events, version 3.0, is when patients experience sensor or motor 
neuropathy (grade 2). Time to event in this case means that the time to the first 
neuropathy event.          
         A secondary neuropathy which is considered as any sensory neuropathy, motor 
neuropathy or neuropathic pain   grade 2 was also tested in the model. In addition to the 
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toxicity endpoints, an efficacy endpoint, the time to first relapse, was also taken into 
evaluation. By the definition of relapse of ALL patients, it included four types of relapse: 
an isolated bone marrow relapse: the presence of ≥ 25% lymphoblasts in a bone marrow 
aspirate following the first complete remission (CR); CNS relapse:Positive 
cytomorphology and > 5 WBC/μL or positive cytomorphology with cerebrospinal 
fluid(CSF) WBC 0-4/μL on two successive occasions; testicular relapse: the histological 
evidence of lymphoblastic infiltration in one or both testes; and combined ALL relapse 
( protocol 9004; protocol 9905). 
2.3 Genome-Wide Association Study 
         An association analysis of genotype frequencies with each phenotype was first 
carried out for the biomarker pre-selection process. Each phenotype was treated as a 
binary variable; ie, 1 for the event and 0 for no event.  Clinical, demographic, and 
population stratification variables were also tested as covariates in the regression analyses. 
Genotype frequencies were evaluated in dominant, recessive and additive (gene-dose) 
models, and these analyses were performed in R coxph package (Therneau et al., 2014).  
2.4 Genotype Imputation 
         To infer missing genotypes in the data, an imputation software called MACH (Li et 
al., 2009; Li et al., 2010) was applied to impute sporadic missingness of typed markers 
using a phasing approach with the following command: mach1 -d sample.dat -p 
sample.ped --states 200 -r 50 --dosage --prob --geno –phase After the imputation, the 
genotypes were coded as 0, 1 and 2 for minor allele copies.  
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2.5 LASSO Penalized Regression Model 
         After the association analysis in the GWAS study, each SNP was extracted with a 
statistical p-value and a hazard ratio
 
(Therneau et al., 2014).
   
Then, the SNPs were 
selected based on a pre-selection process which was defined in the modeling strategies 
(Figure 7.1).  Frist, the smallest p-value across three genetic models was identified for 
each SNP. After ranking the p-value of each SNP, three following signature models were 
conducted. In model 1, only demographic and clinical variables were tested in the 
association. In model 2, in addition to variables tested in model 1, SNPs with a p-value < 
1x10
-5 
were included in the association analysis. Furthermore, an extended SNP pool with 
p-value <1x10
-4 
were tested in model 3. The same modeling sequence was also examined 
with SNPs selected from only the dominant and additive models. 
         A particular feature of GWAS studies specifies that the dimension of the predictor 
space (number of genes) is typically larger than the number of samples (Sohn et al., 2009; 
Tibshirani et al., 1997; Benner et al., 2010; Fan et al., 2002). A penalized log partial 
likelihood in the LASSO method was utilized in conjunction with the proportional 
hazards model. The LASSO solution proposed by Tibshirani (Tibshirani et al., 1997) and 
Fan and Li (Fan et al., 2002) allows for parameter estimation by minimizing the log 
partial likelihood. The log partial likelihood was calculated using the following equation: 
  (  = ∑ (       ∑ exp (                 ) subject to ∑|  |    where s is a tuning 
parameter. If ∑|  |   , the regression coefficients are shrunken toward zero. In this 
context, imputed SNPs as well as clinical and demographic variables were analyzed in 
relation to the phenotype using the LASSO penalized Cox model in R package glmnet 
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(Friedman et al., 2010).  A cross-validation was implemented in the program to optimize 
lambda for model selection.  
2.6 Model Evaluation  
         The predictive accuracy of a survival model was summarized using extensions of 
the proportion of variation explained by the model. The time-dependent sensitivity and 
specificity, and time-dependent receiver operating characteristic (ROC) curves were 
applied to evaluate the survival regression model by focusing on the correct classification 
rates.  For survival data, there are several potential extensions of cross-sectional 
sensitivity and specificity. In this study, a cumulative/dynamic approach was performed 
to define the population who is classified as either a case or a control on the basis of vital 
status at time t at any fixed time t. Each individual serves as a control for time t < Ti , but 
as a case for time t  Ti  (Heagerty et al., 2000; Heagerty et al., 2005). At any time point t, 
the sensitivity and specificity for a given threshold c are defined as  
Sensitivity: P (Mi > c | Ti   t) 
Specificity: P (Mi  c | Ti  > t) 
Where Ti  is either time to event or censoring for the subject i, Mi is a risk factor for the 
subject i. Furthermore, the nearest neighbor estimation (NNE) approach was applied to 
create a monotonic ROC curve. The sensitivity and specificity are based on joint and 
marginal distributions for time to event and risk factors, and the estimators of sensitivity 
and specificity were defined below 
  (  =
∑ (     
 
  e e   (      is the indicator function. 
   (    =
 
 
∑     ( | =     (     )  
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 ̂  ( | =    = ∏ {  
∑  (| ̂ (  )  ̂ (   |     (        
∑  (| ̂ (  )  ̂ (   |     (       
}          with a chosen 
  =  
     
Where  ̂ (   is an estimator of the risk factor distribution;  ̂  (     is an estimator of the 
joint survival function;  ̂  ( | =     is an estimator of the conditional survival 
function with a specific risk factor. 
Then, the sensitivity and specificity were defined as 
Sensitivity=
    (      (    
     (     
 
Specificity=  
   (    
   (     
 
2.7 Signature Models Validation  
         A signature for each phenotype constructed in the training data (POG 9904 and 
9905 trials) was further validated in a completely independent validation dataset (POG 
9906 trial) with a total of 122 ALL patients. To do so, SNPs which were identified in 
both training and validation data were first mapped. Among these selected SNPs and 
demographic variables, the estimated coefficient of each covariate from the univariate 
analysis in the training data were multiplied by the value of covariate in the validation 
data to generate a predictive risk score for each ALL patient in the validation data. 
2.8 Clinical Application  
         To consider the clinical application, sensitivity and specificity calculated from ROC 
curves were evaluated to determine the cutoff for the risk score. Patients with a risk score 
less than the threshold were considered to be a low-risk group. In contrast, those who 
have a score above the threshold were assigned to be a high- risk group.                                                                               
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3. Results 
        To avoid the collinearity problem and high-dimensionality, a LASSO penalized Cox 
proportional hazard model was applied to the analysis. Different to a typical Cox 
proportional hazard mode, the LASSO approach cannot handle missing genotypes which 
were observed commonly in the high-dimensional genome wide association study. In 
order to overcome this limitation, an imputation of typed SNPs was performed by MACH 
based on the haplotype of the dataset. At the initial stage of the model development, a 
signature model was introduced independently to test SNPs selected from each genetic 
model. As we moved forward to design a more comprehensive signature model, the 
strategy was modified and represented in Figure 7.1. For each phenotype, a minimum of 
p-value of each SNP was selected across either strategy 1, which included all three 
genetic models, or strategy 2, which only included the dominant and additive models. As 
Figures 7.2 A to L showed, the LASSO regression model in glmnet package allowed 
conducting a 10-fold cross-validation to optimize lambda which is a parameter to 
determine which coefficient was shrunken toward 0. The y-axis represented the partial 
likelihood error. The line on the right was drawn at the minimum error, and the other was 
drawn at the maximum value of lambda within 1 standard error of the minimum. At the 
maximum lambda, the LASSO coefficient paths were shown in Figures 7.2 M to X. The 
model was further evaluated by the ROC curves. This ROC analysis provided tools to 
select the optimal model, and the accuracy of the model was measured by the area under 
the ROC curve (AUC). The accuracy of the model represents how well the model 
separates the group being tested into those with and without the phenotype in question. 
For the primary neuropathy, no biomarker was selected in model 1 when only the 
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demographic and clinical factors were considered. The AUC is 0.7069419 in model 2, 
and the AUC increases to 0.9472682 in model 3. When the model was tested under the 
strategy of considering all three genetic models, the numbers of SNPs were increased in 
the test. As a result, the calculated AUCs improve to 0.908435 in model 2 and 0.9710504 
in model 3, respectively. For the secondary neuropathy, the AUC is 0.5412067 without 
considering any genetic information. Furthermore, the AUCs increase to 0.7668192 and 
0.9254674 in models 2 and 3, respectively. When the SNPs from the recessive model 
were also tested, the AUCs are 0.8876722 and 0.9691573 in models 2 and 3, respectively. 
The numbers of the selected predictors in each model were listed in Figures 7.3 E to F. 
For relapse, the accuracy of the model was evaluated in a time dependent manner. As the 
duration of clinical follow-up lasted almost 10 years for some patients, the sensitivity and 
specificity of the model at four time points (1, 2, 4 and 8 years) were evaluated.  In 
Figures 7.4 E to F, the AUCs are between 0.687354 and 0.712445 across four time points 
in model 1. Under the strategy 1, the AUCs are between 0.731131 and 0.756252 in model 
2 and between 0.925097 and 0.933578 in the model 3 across time points. When 
additional SNPs selected from the recessive model were tested, the AUCs are between 
0.837579 and 0.861887 in model 2 and between 0.926813 and 0.969303 in model 3. 
Overall, signature models with model 3 approach predicted both neuropathy and relapse 
more accurately than the models 1 and 2 based on the ROC curve evaluation. 
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Figure 7.2. Cross-validation and LASSO coefficient path plots for primary neuropathy, 
secondary neuropathy and relapse.  
A-L represents the 10-fold cross-validation result with Model 2 and 3 as well as Dom/Rec/Add 
and Dom/Add genetic model strategies. 
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M-X represents the LASSO coefficient path result with Model 2 and 3 as well as Dom/Rec/Add 
and Dom/Add genetic model strategies. With the selected lambda, the coefficient of marker 
shrunk toward 0 on the right. 
Dom: dominant model; Rec: recessive model; Add: additive model. 
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       Furthermore, model 3 was used to identify patients who are at high risk of having an 
event based on selected sensitivity and specificity. A threshold of sensitivity at 
0.90308144 and specificity at 0.901608868 were selected for primary neuropathy. The 
survival curves of high risk vs. low risk groups were plotted in Figures 7.5A and B.  For 
the secondary neuropathy, sensitivity at 0.901325 and specificity at 0.900154 were 
selected to distinguish the survival of high risk vs. low risk groups in Figures 7.6A and B. 
Survival curves of high risk vs. low risk groups based on sensitivity at 0.900651992 and 
specificity at 0.9000682719 for relapse were shown in Figures 7.7A and B.  
         In order to evaluate the model predictability, the signature of each phenotype was 
further validated by predicting the risk score in a new population.  There are 265,126 
SNPs found in both training and validation sets. Among these SNPs, SNPs with p-value 
<1 x10
-3 
in the training set and p-value <1 x10
-2
 in the validation set were then evaluated. 
By taking the median risk score across the population, the time to primary neuropathy 
was compared between group 1 (>median risk score) and group 2 (<median risk score). A 
p-value of 0.00066 was given based on 2 distribution in the log rank test. Similarly, a 
significant p-value of 0.00791 in 2 distribution was observed when comparing the time 
to secondary neuropathy between group 1(>median risk score) and group 2 (<median risk 
score). For the efficacy endpoint, the difference of time to relapse between the two 
groups, based on a cutoff of the median predictive risk score from the validation data, 
was with a p-value of 0.000656. All these findings indicated that the signature of each 
phenotype was well validated in an independent population based on the proposed 
validation scenario. 
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         In addition, to apply the clinical utility of the signature model by identifying 
patients who are less likely to be benefited  from the treatment, patients at high risk of 
relapse were selected by a risk score greater than 222.009734 based on specificity at 
0.9000682719. Furthermore, a subgroup of those patients who are likely to experience 
primary neuropathy was identified based on a risk score greater than 1 at sensitivity of 
0.820777. A total of 48 individuals were identified in this category (Figure 7.8). A sub-
population who is most likely to receive the benefit of the treatment was also classified in 
Figure 7.8. Similar to the primary neuropathy, patients were divided into four sub-groups 
based on the risk assessment of both relapse and secondary neuropathy in Figure 7.9. 
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Figure 7.3. ROC curves  of primary and secondary neuropathy in two genetic model 
strategies and the numbers of tested and selcted biomarkers in the models. 
Dom: dominant model; Rec: recessive model; Add; addtivie model;Dem: demographic and 
clinical factors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                          173 
 
 
AUC  curve 
 
Biomarkers 
 
AUC at each time point 
 
Model 
Strategy 
A 
 
C 
 
 
E 
 
 
 
 
 
 
Dom/Rec/
Add 
B 
 
D 
 
 
F 
 
 
 
 
 
 
 Dom/Add 
 
Figure 7.4. Time dependent ROC of relapse in two genetic models.  
A-B: ROC curves from 1 to 8 years 
C-D: The number of tested and selected biomarkers in model 1 to 3.  
E-F: Area under the ROC curve (AUC) of each model at time 1, 2, 4 and 8 years. 
Dom: dominant model; Rec : recessive model; Add: additive model. 
 
 
 
  
 
 
 
 
 
  Figure 7.5. Survival plot of high risk vs. low risk group of primary neuropathy with (A) sensitivity=0.903081 and (B) specificity=0.901608. 
(A) Patients have risk score greater than 9.15 considered as high risk group; (B) Patients have risk score greater than 7.26 considered     
as high risk group. 
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  Figure 7.6. Survival plot of high risk vs. low risk group of secondary neuropathy with (A) sensitivity=0.901325 and (B)  
  specificity=0.900154. 
  (A) Patients have risk score greater than 8.01 considered as high risk group; (B) Patients have risk score greater than 6.34 considered as high risk       
  group. 
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  Figure 7.7. Survival plot of high risk vs. low risk group of relapse with (A) sensitivity=0.900651 and (B) specificity=0.900068 . 
(A)  Patients have risk score greater than 204.74 considered as high risk group; (B) Patients have risk score greater than 222.01 considered as  
high risk group. 
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Figure 7.8. A graphical representation of the clinical application using the signature model to identify ALL patient in four subgroups (HR 
RE/HR NE; HR RE/ LR NE; LR RE/HR NE; LR RE/ LR NE) based on relapse and primary neuropathy endpoints and their clinical 
recommendation. 
NE: primary neuropathy; RE: relapse; HR: high risk; LR: low risk. 
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Figure 7.9. A graphical representation of the clinical application using the signature model to identify ALL patient in four subgroups (HR 
RE/HR NEP; HR RE/ LR NEP; LR RE/HR NEP; LR RE/ LR NEP based on relapse and secondary neuropathy endpoints and clinical 
recommendation. 
NEP: secondary neuropathy; RE: relapse; HR: high risk; LR: low risk
1
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8
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4. Discussion 
        Our analysis of single nucleotide polymorphism data demonstrated that the LASSO 
penalized regression is capable of identifying pertinent predictors. The LASSO technique 
for variable selection in the Cox model seemed to be a worthy competitor to stepwise 
selection. It is less variable than the stepwise approach and still yields interpretable 
models. The computational time is relatively quick compared to the traditional GWAS 
study. Initially, we expected that the model would not only be capable of predicting time 
to event by a genetic pattern, but also would provide a reasonable prediction in a relative 
small association data set with no statistical significant association identified in the 
GWAS study.  Based on our study design, we constructed three models to compare how 
much information would be enough in the test to generate a reasonable prediction to the 
same phenotype.  As the model performed 10-fold cross-validation, it allowed the 
function to run 10fold+1 times to get the lambda sequence and compute the fit with each 
of the folds omitted. The optimal lambda was selected based on the mean of accumulated 
cross-validated error. This process was done repeatedly in each model and generated a 
unique signature for each phenotype.      
         Based on ROC curve evaluation, the area under the curve of ROCs in model 3, 
which contained demographic and SNPs with p-value <1x10
-4
 across both neuropathy 
and relapse, generally exceeded 0.9. This indicated that the model well predicted patients 
with and without event.  All important findings are subject to replication. This attitude 
allows us to define the most informative SNPs rather than only declaring their global 
significance. Our approach to data analysis is motivated by this consideration. In addition, 
the signature of each phenotype was further validated in the validation data set. In this 
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backward validation, the overlapped SNPs with a predefined p-value threshold were first 
identified; then, the predicted risk scores were calculated for each individual in the 
validation data using estimated coefficients from univariate analysis in the training data. 
As the result indicated a statistically significant separation of patients’ time to neuropathy 
or relapse based on the median of predicated risk score using the log-rank test, this 
validation gave a preliminary overlook of how well the model predicts based on the best 
scenario.  However, the current validation data set, which mainly has a population at high 
risk for treatment failure, may not be the best candidate to validate the signature model. 
Therefore, further analysis needs to be done, not only to validate the model by taking all 
the tested SNPs into consideration which may be more precise in evaluating the signature 
applicability, but also to evaluate the signature in a standard risk disease population 
similar to POG 9904 and 9905 trials. 
         In addition to validating the generalizability of the model, the clinical application of 
the signature model is also a major focus in this study. Clinically, as ALL relapse still 
carries a very poor prognosis and the majority of relapse continues to occur in patients 
without apparent “high-risk” features (Stanulla et al., 2009; Schrappe et al., 2000a; 
Schrappe et al, 2000b), the utility of the signature model becomes meaningful when a 
subgroup of patients who have no benefit from the treatment because of the high risk of 
relapse and neurotoxicity can be predicted and alternative treatments can be 
recommended. Similarly, for those who are either at high risk of relapse or high risk of 
neuropathy, the clinicians can evaluate the cost and effectiveness to recommend dose 
modification.  Those who are less likely to experience toxicity or relapse can be the best 
targets for the treatment and for understanding drug exposure variability. With all these 
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factors taken into account, our signature modeling approach not only provides an 
innovated assessment to high dimensional genomic data for identifying potential 
associations with toxicity and efficacy, but also integrates a statistical model with clinical 
useful application and interpretation.  
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CHAPTER VIII: Conclusions and future directions        
1. Conclusions 
          The major foci of this dissertation were to explore the impact of modeling and  
simulation in drug development and patient care: 1) where a population approach in  
pharmacometrics can be used to understand pharmacokinetics of drugs in humans from a  
translational in vivo model, the covariate effect on exposure variability in a special  
population, the pharmacodynamics of biomarkers for predicting  the clinical outcome of a  
treatment and the evaluation of a trial design based on a simulated virtual population; and  
2) how a statistical modeling approach can be utilized to evaluate the association between  
pharmacogenomic variations, drug-induced toxicity and efficacy to establish a signature  
pattern that determines patients’ risk of experiencing these effects. The analyses from this  
dissertation address limitations of each modeling approach presented.  These limitations  
are tied back to the underlying assumptions in the modeling approach as well as the  
potential sources of variability that can contribute to trial failure and should be accurately 
measured.  This dissertation also points out an integration between different modeling 
approaches which potentially allows more sophisticated understanding of the biomarker 
application and helps to capture disease status and treatment effect across a spectrum of 
modeling approaches and data types.  
         Based on the major findings outlined above, the overarching conclusion of  
each modeling and simulation application can be drawn concerning the body of work  
presented in this dissertation.  These are: 1) a translational PK modeling approach that  
was able to predict clozapine and norclozapine CNS exposures in humans relating these  
exposures to receptor binding kinetics at multiple receptors; 2) a population  
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pharmacokinetic analysis of a study of sertraline in depressed elderly patients with  
Alzheimer’s disease (DIADS-2) identified site specific differences in drug exposure 
contributing to the overall variability in sertraline exposure; 3) the utility of a longitudinal  
tumor dynamic model developed by the Food and Drug Administration for predicting  
survival in NSCLC patients drawn from NCI funded studies, including an exploration of  
the limitations of this approach; 4) a Monte Carlo clinical trial simulation approach that 
was used to evaluate a pre-defined oncology trial with a sparse drug concentration  
sampling schedule with the aim to quantify how well individual drug exposures, random  
variability, and the food effects of abiraterone and nilotinib were determined under these  
conditions; 5) a time to event analysis that facilitated the identification of candidate genes  
including polymorphisms associated with vincristine-induced neuropathy from several 
association analyses in childhood ALL patients; and 6) a LASSO penalized regression  
model that predicted vincristine-induced neuropathy and relapse in ALL patients and  
provided the basis for a risk assessment of the population. Each of these conclusions is  
summarized followed by further directions in the section which follows. 
A. A translational PK modeling approach that predicted clozapine and norclozapine 
CNS exposures in humans relating these exposures to receptor binding kinetics at 
multiple receptors 
         From a clinical perspective, it is important to understand the broad receptor 
coverage of clozapine that is thought to account for clozapine’s unique superiority in 
treatment resistant schizophrenia. With the innovation and improvement of measurement 
techniques, clozapine concentrations now can be measured at the target site using 
microdialysis so that the concentration can be more precisely related to response at the 
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effect site (Derendorf et al., 2000; Chefer et al., 2009; Jacobson et al., 2013). As part of 
this dissertation (CHAPTER II), we demonstrated that the proposed PK model can be 
extrapolated to predict human systemic exposure including clozapine brain 
concentrations and associated receptor occupancy profiles in humans at clinically 
relevant doses.  In addition, the model simultaneously captured the parent-drug and 
metabolite in the system.  This is relevant as norclozapine also has activity at multiple 
receptors in the CNS that could contribute to response (Bishara et al., 2008). This 
modeling approach could form the foundation for the design of the future comprehensive 
PK-PD models as well as extend our understanding of clozapine’s complex behavioral 
effects in humans. Furthermore, this model framework can serve to support the discovery 
of a new drug entity that may share the same mechanism of action as clozapine. 
B. A population pharmacokinetic analysis of a study of sertraline in depressed elderly 
patients with Alzheimer’s disease (DIADS-2) identified site specific differences in drug 
exposure contributing to the overall variability in sertraline exposure 
         This is the first population pharmacokinetic (PPK) study of sertraline focusing on 
AD patients with depression. Compared to younger patients, the elderly have a longer 
half-life, but there was no difference between elderly healthy volunteers in the literature 
and these AD patients in PK characteristics. In addition, a covariate analysis was 
conducted to explore whether the variability of the PK parameter estimates could be 
explained by patient specific characteristics. Based on the analysis, the clinical site was 
the only significant covariate explaining variability in the CL/F change. The clinical 
implications for subjects at the outlying site would be important if this represented a true 
bias in subject selection. As we discussed in CHAPTER III, no significant difference in 
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demographic or clinical attributes between this study site and the others were found; 
therefore, a potential source of variation is the implementation of study procedures at this 
site. In conclusion, site variability in trial procedures is critical to the validity of multi-site 
trials, and population pharmacokinetics may prove helpful in this assessment. With the 
application of the population PK model approach, a close monitoring of dosage regimen 
and administration is recommended in the future multicenter study especially with sparse 
PK sample collections so that patients would not exposed to unnecessary harm. This can 
also minimize what may be artificial systematic differences in exposure, and therefore 
potentially confound on the interpretation of response and/or toxicity. 
C. The utility of a longitudinal tumor dynamic model developed by the Food and Drug 
Administration for predicting survival in NSCLC patients drawn from NCI funded studies, 
including an exploration of the limitations of this approach 
         Previous studies have shown that modeling and simulation is an efficient means to 
support decision making at the Phase 2 to Phase 3 transition in drug development (Claret 
et al., 2012), therefore, it was thought that this longitudinal tumor model could serve as a 
framework to predict clinical outcomes of cancer patients ideally resulting in smaller 
trials with shorter observation  periods (Adjei et al., 2009; Dhani et al., 2009; Maitland et 
al., 2011; Maitland et al., 2011; Mandrekar et al., 2010; Stein et al., 2011; Yap et al., 
2010).  Based on this initial idea, we demonstrated in CHAPTER IV that a modeling 
strategy to assess the tumor load dynamics found that the tumor model parameter 
estimates of tumor shrinkage and progression rates were both lower than the findings 
from the previous FDA large registration trial data.  However, when the FDA trial was 
reduced to a similar size as our CALGB30203 study and patient characteristics matched, 
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the parameter estimates became comparable. The lower parameter values for tumor 
dynamics from the model using the data from the CALGB trials suggested that the 
prediction of overall survival using this metric was likely impacted by the sample size 
and heterogeneity in the tumor presentation. In addition, a simplified time to tumor 
growth (TTG) parameter was observed to be more robust in predicting overall survival in 
our small trial as a single factor, but the clinical interpretation and utility need to be 
further explored.  In conclusion, the data quality is critical for a model to give a 
meaningful contribution to predicting patient outcome. The limitations inherent in tumor 
measurement can lead to the misrepresentation of the true tumor growth dynamic. This 
variation can be more problematic when the sample size is small. Further analysis is 
required to explore the utility of the tumor dynamic model in predicting patients’ survival 
outcomes using alternative measurements such as automated capture of the three-
dimensional tumor volumes from raw CT scan data (Schwartz et al., 2000). It appears 
that this approach may be more accurate in describing the tumor change over time, and 
potentially eliminates the inter-rater variability from the traditional sum of the longest 
diameter measurement carried out by radiologists. In addition, a simulation approach 
could be applicable to evaluate how different level of variance of the tumor 
measurements can affect the overall tumor model parameter estimates.  Until more 
precise and/or accurate measures are available, it will also be difficult to ascertain the 
true relationship between tumor loads (especially across tumor types that may be treated 
with agents that are –static instead of –cidal in their effects) and patient specific outcomes 
such as progression free survival and overall survival. 
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D. A Monte Carlo clinical trial simulation approach was used to evaluate a pre-defined 
oncology trial with a sparse drug concentration sampling schedule with the aim to 
quantify how well individual drug exposures, random variability, and the food effects of 
abiraterone and nilotinib were determined under these conditions 
         Food intake is one important contributor to variability in oral bioavailability (Singh 
et al., 2004; Winstanley et al., 1989; Gu et al., 2007) in particular for some of the newer 
oral anticancer agents such as abiraterone and nilotinib (Ryan et al., 2010; Yin et al., 
2010). This can cause a significant impact on systemic drug exposures that can lead to 
drug toxicity and/or therapeutic failure (Koch et al., 2009; Kang et al., 2010).  We 
demonstrated in CHAPTER V how a clinical trial simulation using a Monte Carlo 
method under the framework of a Pop PK approach provided understanding of a clinical 
oncology population pharmacokinetic trial design with a random sampling schema.  More 
specifically, we were able to quantify how well this design and the data collection 
scheme associated with it and were able to capture the variability and the magnitude of 
individual drug exposure in the presence of a large food effect in nilotinib and abiraterone 
trials. This simulated approach facilitated an early evaluation of the proposed trial design. 
However, clinical trial simulations are generated based on many trial assumptions, and 
these assumptions may include uncertainty.  For future studies, different scenarios with 
underlying assumptions can be tested to optimize the design. With the limitations of 
current analysis discussed in CHAPTER V, additional components such as a drop-out 
pattern of the trial and patient compliance, which may vary in the clinical practice setting, 
should be explored in future analyses. 
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         This study emphasizes the importance of addressing trial designs where intensive 
sampling cannot be obtained and yet there is a need to understand the drug exposure 
characteristics to what are otherwise medications with highly variable pharmacokinetic 
dispositions.    
E. A time to event analysis facilitated the identification of candidate genes including 
polymorphisms associated with vincristine-induced neuropathy from several association 
analyses in childhood ALL patients 
         Vincristine is among the most commonly used anticancer agents, however, little is 
known regarding its disposition and optimal dosing.  This gap in knowledge can lead to 
negative clinical outcomes such as toxicity due to drug overdosing or lack of efficacy due 
to sub-therapeutic dosing. Vincristine is associated with highly variable cumulative dose-
dependent peripheral neuropathy. To explore the association between germline variants 
and VIPN in pediatric ALL patients, a genome-wide association analysis was carried out 
initially. The analysis was expanded to examine the association using gene enrichment 
analysis. In both analyses, we identified several genetic loci associated with incidence of 
 grade 2 VIPN.  Based on the top-ranked SNPs, 31 genes were found in an association 
with either primary or secondary neuropathy.  In CHAPTER VI, a discussion was 
carried out to identify those candidate genes and their corresponding pathways. In this 
stage of discovery, we found that there are many genes which are indirectly associated 
with the mechanisms of leading vincristine-induced neuropathy, but we believe these 
findings can be potential focuses for the future in vitro studies after association is 
confirmed by sequencing an independent data set from a multi-center trial. Furthermore, 
the candidate genes selected from the association analysis were evaluated in the 
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interactive pathway analysis and gene expression analysis. Based on both the GEO and 
eQTL databases, few additional gene candidates appeared in association with neuropathy. 
In conclusion, we came across some similar correlations observed from different 
associations and data approaches that provided additional confirmation of the findings. 
These findings have significant potential clinical relevance given the widespread use of 
vincristine in treating childhood cancers. 
F. A LASSO penalized regression model predicted vincristine-induced neuropathy and 
relapse in ALL patients and provided the basis for a risk assessment of the population 
         As the previous section (CHAPTER VI) discovered the association between 
germline variants and VIPN using multiple association analyses, this chapter focused on 
an alternative modeling approach to identify a genetic signature pattern which allows 
predicting the traits and avoid the collinearity in fitting which is a common limitation 
found in typical Cox proportional hazards model (Sohn et al., 2009). By performing a 
LASSO penalized regression model, a signature was developed not only for neuropathy 
but also for relapse independently as previous study showed no correlation between two 
phenotypes. Under different model strategies, we demonstrated that a unique genetic 
signature was capable to predict neuropathy or relapse with reasonable precision based on 
ROC evaluations. In order to indicate the clinical utility of the signature model, a risk 
assessment was carried out under the structure of genetic signature. In sum, the whole 
population was divided into four major groups based on the statistical threshold for both 
relapse and neuropathy. This identification would provide clinicians an initial guidance 
for dose recommendations which might result in a more efficient treatment plan and 
avoid unnecessary drug exposure to patients. The utility of the signature model seems 
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promising in predicting time to event, but a more comprehensive validation plan will 
need to further explore and test the model predictability. In fact, instead of building a 
signature only based on typed SNPs from the genotyping data, an additional approach 
was suggested to expand the signature by examining the untyped SNPs from the 
imputation. This approach might provide a more representative pattern of predictive 
signature across different populations and data, but the quality of imputation data needs 
to be carefully evaluated as we found to be a challenge initially when we imputed our 
training data. In terms of clinical utility of the signature, a challenge we are facing right 
now is if there is a surrogate endpoint which can help us to understand the disease and 
treatment effect as early as possible and enhance the application of the modeling 
approach. To consider this, minimal residual disease which was suggested by some 
studies (Campana 2010; Borowitz MJ, et al., 2008) as an important predictor of ALL 
relapse may be valuable to explore in this case. 
         Overall, this dissertation demonstrated the utility of modeling and simulation in 
various study design scenarios and its application and contribution for the future studies 
in drug development and patient care. Although different population and disease were 
focused in each chapter to explore a specific underlying modeling approach, the whole 
dissertation provided a projection of how each approach can be integrated in drug 
development process. An integration of multiple modeling approaches is also suggested 
by this dissertation to overcome the challenges and to examine the proposed solutions for 
the limitations of the current modeling approach.  As recalled the drug development 
process in Figure 1.1, if there is a new compound targeted at early drug discovery phase, 
a combination of preclinical and translational modeling approach (CHAPTER II) can 
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capture its exposure-response relationship in vivo system, extrapolate a first to human 
dose and further predict some pharmacological relationships which have not been 
assessable in the human system. As this new compound is moved forward to the clinical 
phase, PPK model (CHAPTER III) can serve as a tool to continuously evaluate its 
exposure-response relationship, quantify the level of variability and identify covariate 
effect. This approach can be further expanded to predict PK in a special population such 
as elderly or another disease population. In addition to understand the PK profile of this 
new compound, assessment of the dynamics of a biomarker (CHAPTER IV, VI and VII) 
can provide insight into the disease progression and capture a therapeutic drug effect of 
this compound which might be useful for early go/no go decision or personalized 
medicine later on  before the clinical endpoints are available. Meanwhile, a clinical trial 
simulation (CHPATER V) can explore various dosage regimens of the compound and 
optimize the trial design which might allow reducing the numbers of the studies and be 
more efficient and informative in bridging studies from one phase to another. As a 
demonstration of how these approaches emphasized in the dissertation can be integrated 
in the drug development process, we also need to be aware that there are many more 
assessments could be done by modeling and simulation in the process.   
         In summary, modeling and simulation is a tool that enhances our understanding of 
pharmacokinetics and pharmacodynamics for specific drug entities and provides critical 
recommendations for dose selection and treatment plans. Leveraging the findings from 
biological studies, it will continue to be an essential element in drug development and 
patient care.  
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